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 Periodontal disease is a known risk factor for diabetes in the dental 
literature, where most studies were cross-sectional in design and include 
individuals with normoglycemia and those with pre-diabetes in the same 
comparison groups. Despite the discussion of a bi-directional relationship 
for the past twenty years, evidence to support the effect of periodontal 
disease on the risk of incident diabetes is lacking. This dissertation 
explored the increased risk of insulin resistance and diabetes in response 
to oral inflammation. We hypothesized that oral inflammation increases 
the risk of insulin resistance and diabetes. This thesis consisted of three 
aims to test this overall hypothesis. The first aim used cross-sectional data 
from the 6, 138 individuals in the Atherosclerosis Risk in Communities 
(ARIC) Study, a community-based prospective cohort. Compared to 
individuals in Category I (probing depth (PD) <3mm and bleeding upon 
probing (BOP) 10%), the odds ratio for impaired fasting glucose in those 
with severe periodontal inflammation (Category V- one or more sites with 
a PD 4mm and BOP 50) was 1.5 (95%CI:1.1-2.1). A modest 
association between serum antibody levels to periodontal pathogens 
(Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans) 
and gingival crevicular fluid levels of IL-1 and PG-E2 and pre-diabetes 
status was suggested but did not reach statistical significance.  The 
second aim used the same population, where of the total 5,819 eligible 
participants at baseline (ARIC Visit 4), 1,967 individuals developed 
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incident type 2 diabetes after a mean of 13.8 years of follow-up.  Incident 
diabetes was assessed with yearly telephone interviews and self-reports 
from study participants. In multivariable analyses using the Cox 
proportional hazards model, when compared to Category I (probing depth 
(PD) 3mm, bleeding upon probing 10%), the hazard ratio of incident 
diabetes was the highest with early periodontal clinical measures of 
inflammation as found in Category II (probing depth (PD) 3mm, bleeding 
upon probing >10%) (HR=1.4, 95%CI: 1.1-1.7,p<0.001) after adjustment 
for sex, age, race, education level, smoking status, physical activity, total 
caloric intake, waist circumference, hypertension, previous cardiovascular 
disease, family history of diabetes, and HDL cholesterol levels. Compared 
with individuals in Category I, with minimal bleeding and probing 
measures, the hazard of incident diabetes appears to be 1.2 times higher 
(95% CI: 1.0 – 1.4, p<0.001) in adults with moderate clinical periodontal 
inflammation (Category IV-one or more sites with PD4mm, bleeding upon 
probing >10% &<50%) and 1.3 times higher (95% CI: 1.0- 1.6, P<0.001) in 
adults with advanced clinical periodontal inflammation (Category V- one or 
more sites with PD4mm, bleeding upon probing 50%). The third aim 
was a survey of 100 Washington DC area Periodontists, to assess the 
attitudes and beliefs of these specialists towards the relationship of 
periodontal inflammation and the risk of diabetes, and how these beliefs 
influenced the standard of care in treating dental patients. This survey 
(respondents n=39) found that practicing periodontists were aware of the 
 iv 
association between periodontal disease and onset of type 2 diabetes 
(92.9%agreed/ strongly agreed).  These respondents appeared to be 
aware of the importance of HbA1c testing in assessing glycemic control, 
whether this test was performed in the dental office or medical setting. The 
results of this dissertation demonstrated that clinical periodontal 
inflammation was associated with an increased risk of pre-diabetes and 
subsequent incident diabetes. In addition, local periodontists understood 
the importance of the relationship between diabetes and periodontal 
disease in treating periodontal patients in clinical practice. Interventional 
studies are needed in the future to test whether prevention of the onset of 
periodontal inflammation reduces pre-diabetes and incident diabetes. 
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Background and Rationale 
 
 Type 2 diabetes is a known risk factor for diabetes in the dental literature, 
where most studies were cross-sectional in design and included individuals with 
normoglycemia and those with pre-diabetes in the same control groups. Despite 
the discussion of a bi-directional relationship for the past twenty years, evidence 
to support the effect of periodontal disease on the risk of incident diabetes is 
lacking. This dissertation will explore the increased risk of insulin resistance and 
diabetes in response to oral inflammation. Figure 1 illustrates the conceptual 
model, where exposure to periodontal inflammation, as measures by clinical 
measures and systemic markers specific to this periodontal disease exposure, 




Figure 1- Conceptual Model 
 
 
Type 2 Diabetes Mellitus and Established Risk Factors  
 
 
Type 2 diabetes mellitus, previously called non-insulin dependent diabetes 
mellitus or adult onset diabetes, is the most prevalent form of diabetes and is 
characterized by hyperglycemia resulting from resistance to the effects of insulin 
or a defect in insulin secretion. In healthy individuals, when the level of blood 
glucose increases, insulin is released from the pancreas to stimulate cells to 
remove glucose from the blood. In patients with type 2 diabetes, this high blood 
glucose level remains high, while these individuals are asymptomatic in early 
stages of disease and are often undiagnosed for several years. Symptoms of 
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hyperglycemia include polyuria, polydipsia, polyphagia, weight loss, fatigue and 
blurred vision. Increased susceptibility to infections may also be seen. 1 
 
Diabetes affects approximately 25.8 million Americans, which is over 11% 
of the adult poulation.2 It has been estimated that the global burden of diabetes 
will increase by 54% in twenty years with a prediction of 439 million adults, or 
10% of the adult population worldwide having this disease.3 Risk factors for type 
2 diabetes include older age, obesity, and family history of diabetes, 
hypertension, high cholesterol levels and history of vascular disease. Additionally 
women with polycystic ovary syndrome have an increased risk of diabetes. The 
African –American, Hispanic Americans, Native Americans, Asian Americans, 
and Pacific Islanders have higher risk of diabetes, compared to 
White/Caucasians in the United States.4 Modifiable lifestyle factors include 
smoking cessation, increasing physical activity level, weight loss, and healthy 
diet.5 
 
Diabetes Complications and Burden in the United States  
 
The classic complications of type 2 diabetes include macrovascular 
disease (e.g. cardiovascular disease), microvascular disease (e.g. retinopathy, 
nephropathy, neuropathy), and altered wound healing. 6 
 
Cardiovascular disease appears to be more prevalent in individuals with 
type 2 diabetes than in those without diabetes.  Compared to individuals without 
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diabetes, ischemic heart disease rates have been found to be about 14% higher 
in 18 to 44 years of age, three times higher in 45-64 years of age, and almost two 
times higher in 65 years of age or older.7  
 
Diabetic retinopathy is the leading cause of blindness in adults 20 to 64 
years of age with 12,000 to 24,000 new cases each year in the United States.  A 
national population-based survey found 25% of all individuals with diabetes 
suffered from visual impairment, which was double the proportion of those 
without diabetes.8 
 
Diabetic nephropathy accounted for over 40% of new cases of end-stage 
renal disease in the United States. Individuals with diabetes are the fastest 
growing group of recipients of dialysis and kidney transplantation in the country.9 
 
Lower extremity disease, which includes peripheral neuropathy and 
peripheral arterial disease, results in increased rates of amputations in people 
with diabetes. Of an estimated 15 % of diabetic adults diagnosed with foot ulcers, 
up to 43% will progress to lower-extremity amputation due to poor wound 
healing.10 Approximately 47% of people with diabetes had at least one lower-
extremity condition (peripheral artery disease, peripheral neuropathy, insensate 
feet, ulcer, or lower-extremity amputation). 11 
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Mortality among individuals with diabetes is twice that of those without 
diabetes and is the fifth leading cause of death.12 A meta-analysis of 10 studies 
found that the relative risk of death was 1.85 (95% CI: 1.47-2.33) in men and 
2.58 (95% CI: 2.05-3.26) in women when comparing adults with diabetes to 
those without diabetes. 13  Type 2 diabetes is now considered an epidemic in the 
United States and its complications account for over 130 billion dollars of health 
care costs in this country.14 It is predicted to be one of the most common 
diseases in a few decades and is projected to affect at least half a billion people.3 
 
Major Clinical Trials of Prevention of Type 2 Diabetes Mellitus   
 
The pivotal diabetes prevention trials, including the Diabetes Prevention 
Program (DPP) trial, the Finnish Diabetes Prevention Program, and the China Da 
Qing Diabetes Prevention Study, have shaped what we know about diabetes 
prevention.15,16,17 (Table 1) 
The DPP trial used lifestyle interventions including weight loss, physical 
activity, and prescription medication in adults with pre-diabetes (impaired glucose 
tolerance).  This study showed that intensive lifestyle intervention reduced the 
development of diabetes by 58%. This study also found that lifestyle changes 
were more effective than the use of metformin (31%) in reducing diabetes onset 
when compared to placebo.15 
The Finnish Diabetes Prevention Study (DPS) used intensive lifestyle 
intervention in its intervention group involving individualized nutritional counseling 
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from a nutritionist, circuit type resistance training, and advice to increase overall 
activity during the first year, followed by a maintenance period. This resulted in 
3.5 kg weight reductions over 3 years. During the first 3 years of the study, 22 
adults (9%) in the intervention group and 51 (20%) in the control group 
developed diabetes (P= 0.0001). 16 
China’s Da Qing Diabetes Prevention Outcome Study randomly assigned 
542 patients with impaired glucose tolerance into one of three intervention 
groups (diet, exercise or diet plus exercise groups) or a control group consisting 
of only a physical exam.  With 6 years of lifestyle intervention, they found a 47% 
reduction in the incidence of severe retinopathy over 20 years due to the reduced 
incidence of diabetes (77.4% developed diabetes at follow–up in the treatment 
group vs. 90.3% developed diabetes in the control group).17 
However, a meta-analysis of randomized educational and behavioral 
interventions (ranging form 1-19 months) in individuals already having type 2 
diabetes found only modest improvements (0.43%) in glycemic control (with 
follow-ups ranging form 1-16 months) with these approaches. 5 This study 
recommended more research be conducted to define the interventions needed to 
produce consistent improvements in glucose control after the onset of diabetes.
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Placebo 10 yr follow-up 
Reduction in diabetes by 34% (24-42%) 














3 yr follow-up 
Weight reduction (3.5 kg) in intervention 
vs. control (0.9kg) with improved 













6 year follow-up 
47% reduction in severe retinopathy in 
combined intervention group attributed to 
reduced incidence of diabetes. 
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Periodontal disease definition  
 
Periodontal disease is defined as loss of attachment of the periodontium, 
whereby gingival epithelial cells and connective tissue attachment, and bone 
around the tooth migrate apically (downwards) away from the cemento-enamel 
junction. This loss of periodontal tissue is caused by the host response to mostly 
gram-negative bacteria and their toxins found in plaque. It is quite common in the 
U.S. adult population and is often seen clinically and radiographically after the 
age of 35 years old, with moderate periodontitis affecting 40-60% of adults and 
advanced peridontontitis affecting 10-15% of the U.S population.   19  
 
Figure 2:Periodontium: Healthy vs. Disease63 
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Type 2 Diabetes and Clinical Periodontal Disease 
 
 
There is a clear relationship between the degree of hyperglycemia and 
gingival inflammation.18 In addition, type 2 diabetes is a known risk factor for 
perioontontitis in the dental literature.19 
 
Four studies were identified that evaluated the longitudinal glycemic 
control in patients and their association with periodontal health.20 21 22 23These 
studies all controlled for age and smoking, but the other confounders varied 
considerably. All studies used partial mouth periodontal exams and the outcomes 
assessed for glycemic control varied for each study. These studies may not be 
generalizable to the general population in the United States. (Table 2)  
 
 
A meta-analysis of 10 interventional studies of periodontal treatment found 
that successful periodontal therapy did not result in statistically significant 
changes in glycemic control in diabetic subjects, with 0.57% reduction in A1c 
measures (p=0.82).24 However, most of the studies were small; only 456 subjects 
were included in all ten studies.  Larger studies with randomized clinical trials are 
needed to determine the benefit of periodontal therapy on glycemic control in 
patients with diabetes. 
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Table 2 -Effect of periodontal disease on glycemic control on adults with 
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Periodontal Disease and Systemic Inflammation 
 
 
Acute endotoxemia, by injection of E. coli lipopolysaccaride (LPS) has 
been shown to induce insulin resistance in cell receptors in adipose cells.25 In 
periodontal disease, LPS endotoxin is expressed on cell walls of periodontal 
pathogens such as Porphyromonas gingivalis and Actinobacillus 
actinomycetemcommitans. These endotoxins act via TLR 4 to trigger 
inflammation and loss of periodontal attachment around teeth. While both 
pathogens may be present in active periodontitis, Porphyromonas gingivalis is 
commonly associated with a chronic slowly progressive generalized form of 
periodontal disease and Actinobacillus actinomycetemcommitans is more 
commonly associated with an aggressive form of periodontitis, which can present 
clinically in younger ages. Antibodies are produced to these periodontal 
pathogens. These serum antibody titers are the most specific markers to reflect 
systemic exposure to periodontal pathogens. Inflammatory mediators, such as 
Prostaglandin E2, have also been measured in gingival crevicular fluid (GCF) 
collected from the gingival crevice to assess periodontal disease. 26 
  
Both diabetes and periodontal disease have been found to result in an 
elevation of inflammatory cytokines as a host response.  Gram-negative bacteria 
found in periodontal disease have been found to result in elevated levels of these 
cytokines, such as Prostaglandin E2 (PGE2) in both the gingival crevicular fluid 
and in peripheral blood in diabetic patients with periodontal disease. Individuals 
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with diabetes and advanced periodontal disease had two-fold higher levels of 
PGE2   and Interleukin-, 1β (IL- 1β) when compared to individuals with diabetes 
and milder forms of periodontal disease. 27Similarly, tumor necrosis factor α 
(TNF- α), another cytokine commonly associated with periodontitis, was found to 
exacerbate insulin resistance.28 Salvi et al. however, found only marginal 
elevations of TNF-α in diabetic individuals with periodontal disease when 
compared to non-diabetic individuals with periodontal disease. Interleukin- 1β (IL- 
1β) is expressed in both patients with periodontal disease and diabetes and is 
believed to play a role in the pathogenesis in both diseases.29 Kurtis et al. 
showed that gingival crevicular levels of IL- 1β were highest in individuals with 
diabetes  (2.43 +/- 0.97 ng/ml), followed by those with periodontitis (1.31 +/- 0.92 
ng/ml) and these elevations were significantly higher than those in the healthy 
controls (0.62 +/- 0.58 ng/ml, p<0.05).30 Protein kinase C, produced by 
neutrophils in response to periodontal disease, was found to be highly correlated 
with glycosylated hemoglobin levels (r=0.71 p<0.001). 31 Thus, the hypothesis of 
a bidirectional relationship between periodontal disease and diabetes may be 
due to the inflammatory response to periodontal disease as measured by specific 
serum markers as well as clinical measures. 
 
Systemic inflammatory Markers and Type 2 Diabetes  
 
Markers for inflammation, such as high white blood cell count, predict the 
onset of incident diabetes with an odds ratio of 1.9 (95% CI: 1.6- 2.3) in a 7-year 
longitudinal study of the ARIC cohort including 1, 457 participants without 
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diabetes at baseline.32  C-reactive protein (CRP), an acute phase response 
protein, was elevated in a cross-sectional study of subjects with diabetes.33 
However, CRP has been found to be elevated for reasons other than diabetes, 
such as advanced periodontal disease, obesity, stroke, myocardial infarcts or 
other infections and is not specific to exposure to diabetes. Serum interleukin-1 
beta (IL-1), another measure of systemic inflammation, has been found to be 
elevated in 50 patients with diabetes and gingival inflammation when compared 
to 30 patients with diabetes but healthy gingiva in a cross-sectional study (2.9 +/- 
3.2 pg/ml vs. 1.5 +/- 1.4 pg/ml; p=0.008.) 34 
 
Insulin Resistance at the Cellular Level     
 
Insulin resistance at the cellular level may be a mediator of inflammation 
and type 2 diabetes. Inflammatory cytokines are known to activate cell signaling 
phosphorylation cascades such as MAP-kinase and NFκB pathways.35 These 
pathways have multiple effects on cellular activities to include insulin resistance, 
insulin secretion and further cytokine production. (Figure 3), and the resulting 
associated oxidative stress has been found to be a significant negative modifier 
to antibodies to oral pathogens.36 An animal model inducing periodontal disease 
in lean rats (n=24) found an elevation of fasting glucose (p=0.003), insulin, 
(p=0.008) and insulin resistance (p<0.001) as evaluated through paired analysis 
with Zucker fatty littermates (n=24). 37 The Zucker fatty rat is a known model of 
prediabetes, with hyperinsulinemia, dyslipidemia, and moderate hypertension. 
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This animal study has been the first to look at the progression to a pre-diabetic 
state that can be attributed to the induction of periodontal inflammation as an 
independent risk factor. Periodontitis was found to affect glucose tolerance in 
lean rats when compared to lean rats without periodontal inflammation.  
 
 
Effect of Periodontal Treatment on Type 2 Diabetes  
 
 
Identifying modifiable sources of inflammation might lead to novel 
approaches to prevent type 2 diabetes. Studies aimed at assessing the effect of 
treatment of periodontal disease on metabolic control of diabetes have yielded 
conflicting results. One study found a 10% reduction in glycosylated hemoglobin 
values with non-surgical periodontal and antibiotic therapies in 113 diabetic 
subjects (p=0.04)38 In this study, 5 subgroups of diabetic participants all received 
periodontal scaling and either chlorhexidine oral rinse, low dose systemic 
tetracycline, chlorhexidine rinse and doxycycline, povodine-iodine rinse and 
doxycycline, or placebo (saline rinse). At 3 months post-treatment, the 
doxyclycline treated groups showed the greatest reduction in periodontal 
inflammation with decreases in probing depths and detection of Porphyromonas 
gingivalis.  Other studies however have looked at similar outcomes after 
periodontal treatment in a meta-analysis finding that the overall reduction in 
glycosylated hemoglobin (A1c) in subjects with diabetes mellitus after non-
surgical periodontal therapy was 0.57% for four studies. This reduction was not 
statistically significant (p=0.82).24 These intervention studies all used clinical 
assessment to determine successful periodontal therapy in persons with diabetes 
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compared to those with  normoglycemia . The non-significant effect of 
periodontal therapy on glycoslated hemoglobin does not imply that periodontal 
therapy has no effect on this pathway completely, since glycosylated hemoglobin 
is not sensitive to immediate or short-term effects on insulin resistance, and four  
of the studies ranged from only 2 to 8 weeks duration. 
 
 Thiazolidinione, an anti-diabetic medication used to improve insulin 
sensitivity, has been shown to inhibit LPS Porphyromonas gingivalis induced 
cytokine production in adipocytes in vitro.39Porphyromonas gingivalis is not 
completely eradicated even after successful periodontal therapy. It is biologically 
plausible that the most sensitive assessment of exposure to periodontal 
inflammation involves periodontal pathogens and measures of their systemic 
levels, such as Porphyromonas gingivalis serum antibodies.  
The Directionality of Periodontal Disease and Diabetes 
 
Periodontal disease has been proposed as one source of inflammation 
that might predispose adults to developing diabetes. Though the hypothesis of a 
bidirectional pathway between periodontal disease and diabetes has been 
proposed, few studies have addressed periodontal disease before the 
occurrence of diabetes.19 Periodontal disease has also been shown to increase 
the risk of other systemic conditions such as cardiovascular disease in adults and 
poor pregnancy outcomes.40 41. Localized periodontal inflammation is now known 
to have systemic effects on general health. Compromised oral health may 
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increase the risk of a pre-diabetic status meditated through diet and 
inflammation. However, there are no known published longitudinal clinical studies 
of exposure to periodontitis, which use both clinical exams and systemic markers 


































Main Hypothesis/Study Questions 
 
Our central hypothesis is that periodontal disease leads to systemic 
inflammation and thereby to insulin resistance and future type 2 diabetes. 
To test our hypothesis, we conducted two related analyses—one cross-sectional, 
one longitudinal, using data from community-based cohort study, ARIC Study. 
Finally, a survey to assess the attitudes and beliefs of Periodontists about the 
association of periodontitis with type 2 diabetes was conducted.  
Specific Aim 1 
Hypothesis: 
 
Periodontal disease, characterized by evidence of periodontal disease on 
clinical examination, high serum IgG titers to oral pathogens, and localized oral 
markers in gingival crevicular fluid are cross-sectionally associated with impaired 
glucose tolerance (IGT), and elevated fasting glucose (FG). 
Specific Aim 2 
Hypothesis: 
Exposure to periodontal inflammation, (using clinical exam evidence, 
systemic inflammatory markers and local inflammatory markers), predicts the 
subsequent occurrence of incident type 2 diabetes. 
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Specific Aim 3 
Hypothesis:  
The association of periodontitis with diabetes with type 2 diabetes is 
accepted by local Peridontists in the Washington DC area , and the attitudes and 










The cross-sectional association of periodontal 





Periodontal disease is the most common inflammatory condition 
worldwide and diabetes is quickly becoming a global epidemic. The bidirectional 
pathway of periodontal disease and diabetes is not fully understood. While 
consistent evidence has shown that diabetes is related to periodontitis, emerging 
evidence suggests that periodontal disease may increase the risk of diabetes 
onset.  Using data from the Atherosclerosis Risk in Communities (ARIC) Study, a 
community-based prospective cohort, the associations of clinical measures, local 
inflammatory markers, and systemic markers specific to periodontal inflammation 
with pre-diabetes were assessed. Compared to individuals in Category I (probing 
depth (PD) <3mm and bleeding upon probing (BOP) 10%), the odds ratio for 
impaired fasting glucose in those with severe periodontal inflammation (Category 
V- one or more sites with a PD 4mm and BOP 50) was 1.5 (95%CI:1.1-2.1). A 
positive association between serum antibody levels to periodontal pathogens 
(Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans) and 
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gingival crevicular fluid levels of IL-1 and PG-E2 and pre-diabetes status was 
suggested but did not reach statistical significance, indicating the associations 
between local and systemic markers for periodontal inflammation and pre-




An extensive body of literature consistently identifies the association of 
type 2 diabetes with periodontal disease.42 Impaired glucose tolerance, or pre-
diabetes is a requisite for type 2 diabetes onset. Most published studies have 
focused on the effect of diabetes on periodontal inflammation. 20-23 However, 
most models proposed to explain the relationship between diabetes and 
periodontal disease have focused on a 2-way, bi-directional interaction between 
these two diseases. Certain inflammatory mediators, such as IL-1 and PG-E2, 
have been associated with both diabetes and periodontal disease. (Table 3).  
These inflammatory mediators are inducers of acute phase proteins such as 
CRP, and these mediators have been shown elsewhere to impair intracellular 
insulin signaling. Previous studies that reported the relationship of inflammatory 
mediators common to both periodontal disease and diabetes were small cross-
sectional studies, and included subjects with impaired glucose tolerance in the 
healthy patient category.  
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 This study analyzes the cross-sectional association of periodontal 
disease, (characterized by evidence of periodontal disease on clinical 
examination, high serum IgG titers to oral pathogens, and localized oral markers 
in gingival crevicular fluid) with impaired glucose tolerance (IGT), and elevated 
fasting glucose (FG) from the ARIC (Atherosclerosis Risk in Communities) Study. 
This population is a biracial, ongoing prospective, community based study 
designed to assess clinical and subclinical atherosclerosis in adults aged 45-64 
years of age. While the initial intent of the ARIC cohort design was to study 
cardiovascular disease, this population provides a rich database to assess the 
cross-sectional association of periodontal disease with pre-diabetes. This is the 
first study to assess the association of clinical measures, local inflammatory 
markers, and systemic markers specific to periodontal inflammation with pre-
diabetes. 
 
Our study uniquely looks at a large population of pre-diabetic individuals 
and their; clinical parameters of periodontal inflammation (bleeding upon probing, 
and probing depths); systemic markers of exposure to periodontal inflammation 
(serum IgG levels of antibodies to pathogens Porphyromonas gingivalis and 
Actinobacillus actinmycetemcommitans): and local inflammatory markers of 
periodontal inflammation (gingival crevicular levels of IL-1). The ARIC database 
provided a rich access to clinical, localized, and systemic markers specific to 
periodontal inflammation with which to assess the association of periodontal 
disease with pre-diabetes. 
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Table 3- Studies of the association of markers of periodontal  
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Research Design and Methods: 
Description of Cohort  
 
 
The Atherosclerosis Risk in Communities (ARIC) Study is a community-
based prospective cohort of 15,792 middle-aged adults from four U.S. 
communities. The first examination of participants (visit 1) took place during 
1987–1989, with three follow-up visits taking place: each approximately every 3 
years. The Dental ARIC study, an ancillary study, funded by the National Institute 
of Dental and Craniofacial Research (NIDCR), was conducted during ARIC visit 4 
in 1996 through 1998 and was cross-sectional in design. The Dental ARIC 
consisted of an oral examination, collection of serum, and interviews.  Of those 
15, 792 ARIC cohort members examined at baseline (1987 to 1989), responders 
to a screening interview were selected. Respondents with no teeth or a medical 
contraindication to probing were excluded, while some refused the dental exam. 
A total of 11,656 ARIC participants were seen at visit 4 and 6,792 underwent the 
periodontal examination.  After excluding adults with type 2 diabetes (n=421) or 
missing demographic data (n=133), the number with dental examinations 
decreased to 6,138. In the analysis of serum markers, additional exclusions were 
applied when serum samples were not available or antibody level were not 
readable (n=1,029). Therefore, 5109 adults were included in the analysis of 
inflammatory marker levels. Missing serum samples further reduced the number 
antibody level assessments to 5,109. (Figure 4) 
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Figure 4- Participants in the cross-sectional analysis (doctor diagnosed 







Clinical assessments of periodontal inflammation were defined by two 
assessments: bleeding upon probing and periodontal pockets (rounded down to 
the nearest mm). This definition is consistent with the standard of care in 
assessing the clinical periodontal status. (Appendix- Figure 17) Using these two 
parameters, participants were classified into 5 categories: 46 
 
I) probing depth (PD) 3mm, bleeding upon probing 10% 
II) probing depth (PD) 3mm, bleeding upon probing >10% 
III) one or more sites with PD4mm, bleeding upon probing 10% 
IV) one or more sites with PD4mm, bleeding upon probing>10% &<50% 
V) one or more sites with PD4mm, bleeding upon probing 50% 
 
Serum markers of prior periodontal disease exposure was defined by   
1) serum IgG antibodies to the periodontal pathogens Porphyromonas gingivalis 
and 2) serum IgG antibodies to Actinobacillus actinmycetemcommitans. These 
variables were measured as the level of antibody response to the periodontal 
pathogen Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans 
in Elisa units (EU). Using the upper quartile as the cut-point, the high antibody 
group was compared to the low antibody group (lower three quartiles). 
Porphyromonas gingivalis antibody levels were considered high at 78.93 EU, 
 28 
and Actinobacillus actinmycetemcommitans antibody levels were considered 
high at 144 EU.  The use of the upper quartile for assigning the high antibody 
level group has been used on other studies.51 The normal antibody level in 
periodontal health for these periodontal pathogens has not yet been established.  
 
Local inflammatory markers of periodontal disease were assessed using 
gingival crevicular fluid levels of IL-1 (GCF- IL-1) and gingival crevicular fluid 
levels of prostaglandin (PG-E2). The variable GCF- IL-1 was measured as the 
level of gingival crevicular fluid units (ng/mL). Using the upper quartile as the cut-
point, participants were considered to have high levels of GCF- IL-1 levels at 
146ng/mL. The variable PG-E2 was also measured as the level of gingival 
crevicular fluid units (ng/mL) and a dichotomous variable (high/low) was used. 
Subjects were considered to have elevated levels of PG-E2 levels at 239ng/mL 
using the upper quartile cut-point. Similarly to the antibody levels to P.g and A.a, 
normal levels of IL-1 and PG-E2 in periodontal health have not been 
established.   
 All clinical periodontal measures, as well as serum and gingival crevicular 






Diabetic Status Categorization 
  
Individuals with type 2 diabetes were excluded from this analysis. The 
ARIC visit 4 individuals were classified as having a diabetes diagnosis if any of 
the following criteria were met; self- report of current use of medication for 
diabetes of blood sugar; or a positive response to the question “Has a doctor 
ever told you that you had diabetes (sugar in the blood)?”. Undiagnosed diabetic 
individuals were classified as having fasting glucose of at least 7.0mmol/L 
(126mg/dL); non-fasting glucose of at least 11.1mmol/L (200mg/dL), but no 
doctor diagnosis of diabetes and no self-report of anti-diabetic medication. These 
ARIC definitions at the time of visit 4 were based on the 1997 American Diabetes 
Association criteria. 
 
Participants were asked to fast for 12 hours before the ARIC visit 4 clinic 
visits and to bring all current medications to determine medication use. Glucose 
was measured using the hexokinase method, and individuals were classified as 
having normoglycemia, impaired glucose tolerance, or undiagnosed diabetes, 
using the 2013 American Diabetes Association criteria49  (Appendix Figure 19):  
normal glucose (fasting glucose <100 mg/dL and 2 hour glucose tolerance test 
<140 mg/dL, and no diabetes diagnosis); impaired glucose tolerance (2 hour 
glucose tolerance of 140-199 mg/dL and no diabetes diagnosis); impaired fasting 
glucose (FG from 100-125mg/dL, and 2 hour glucose<140 mg/dL and no 
diabetes diagnosis: or undiagnosed diabetes (FG >125 mg/dL, or 2 hour glucose 
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>199 mg/dL and never been told by doctor that one has diabetes/or no current 




Covariates measured at the visit 4 baseline included sex, age, race, 
education, smoking, physical activity, total caloric intake, BMI, waist 
circumference, hypertension, previous cardiovascular disease, family history of 
diabetes, and high density lipoprotein levels.  Information on age, sex, race, 
smoking, total caloric intake, education level and family history of diabetes were 
based on self –report. BMI (weight in kilograms divided by the square height in 
meters) and waist to hip ratio (in centimeters) were measured with standard 
procedures.47 Prevalent cardiovascular disease was based on self-report, ARIC 
clinical exam, or hospital records. The physical activity was assessed using a 
modified version of the questionnaire developed by Baecke and colleagues, from 
which a sport index was derived, ranging from 1 (lowest) to 5 (highest).48 HDL 
cholesterol levels were measured after dextran-magnesium precipitation. The 
education levels, however were measured earlier, at visit 1 (1978-1989), and 




Baseline differences between characteristics of normoglycemic individuals 
(fasting glucose<100mg/dL & 2hr glucose tolerance test<140mg/dL, and no 
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diabetes), impaired glucose tolerance (2hr glucose tolerance test=140-199mg/dL, 
and no diabetes), impaired fasting glucose (FG=100-125mg/dL, and 2hr glucose 
tolerance test<140mg/dL and no diabetes), and individuals with undiagnosed 
diabetes (FG>125mg/dL   or 2hr GTT>199mg/dL & no diabetes diagnosis) were 
compared for visit 4 using ANOVA tests for continuous variables and 2 for 
categorical variables (Table 4).  Means and frequencies of each potential 
confounder were also determined for each categories of clinical periodontal 
inflammation (Category I-V- Table 5). ANOVA and 2 analyses were used to 
assess the statistical differences across the 5 categories.  
 
 Multiple logistic regression models were fitted to describe the cross-
sectional association between clinical periodontal disease and pre-diabetic status 
after adjustment for potential confounding variables.  Additional multivariable 
analyses were performed to investigate the roles of inflammatory markers 
(antibody levels to periodontal pathogens Porphyromonas gingivalis and 
Actinobacillus actinmycetemcommitans and serum gingival crevicular levels of 
IL-1 and PG-E2) as potential exposure variables. Adjustment for confounding 
factors in these models included sex, age, race, education level, smoking status, 
physical activity, total caloric intake, BMI, waist circumference, hypertension, 
previous cardiovascular disease, family history of diabetes, and HDL cholesterol 
levels. Since waist circumference was highly correlated with BMI (corr=0.89), 
only waist circumference was chosen to remain in the final models. Current 
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smoking status was used in the models due the expected effect on clinical 
periodontal measures.  
 
 In all multivariable models, tests for interactions with pre-diabetic status 
were performed with sex, race, waist circumference and smoking status.  No 
interactions were detected (all P>0.05), and therefore only pooled results were 
presented. All tests of significance were two–tailed, with a  level of 0.05. All 




Baseline characteristics by pre-diabetic status were presented in Table 4. 
All the characteristics were considered statistically different between the groups if 
p<0.05. Compared with individuals with normal glycemia, in this cohort, adults 
with pre-diabetes and undiagnosed diabetes are more likely to be female, African 
American, older, and less educated. Furthermore, individuals with pre-diabetes 
had a higher BMI, waist circumference, history of hypertension, and family history 
if diabetes (P<0.01). There was no difference in total caloric intake (P=0.1253) or 
previous history of cardiovascular disease by category of pre-diabetic status 
(P=0.3020). A subsidiary analysis of baseline characteristics of 4, 864 individuals 
available at visit 4, but excluded from the periodontal examination, was 
performed (results not shown). The individuals excluded from our primary 
analysis had a higher proportion of African-Americans (39% vs. 24%), smokers 
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(19% vs. 13%), increased caloric intake (1773 kcal/day vs. 1587kcal/day) and 
higher body mass-indices (31kg/m2 vs. 28.9kg/m2).    
 
Baseline characteristics by clinical periodontal inflammation status 
(category I-V) were presented in Table 5. Individuals in the categories with more 
severe clinical inflammation were more likely to be female, smokers, and less 
physically active. These periodontal groups also displayed higher caloric intake, 
BMI, waist circumference, hypertension, previous cardiovascular disease, HDL 
cholesterol, fasting glucose and 2 hr glucose tolerance levels. (P<0.01) There 
were no differences in age (P=0.34) and family history of diabetes (P=0.11). 
 
  The distribution of clinical category by glycemic status in 6, 138 ARIC 
Dental Study participants is displayed in Table 6. High proportions of study 
participants (between 29.0% in individuals with undiagnosed diabetes, and 
42.9% in individuals with normoglycemia, P<0.0001) were displayed with 
moderate periodontitis (Category IV periodontal status- one or more sites with 
PD >4mm, bleeding upon probing >10% &<50%). Likewise, the distribution of 
inflammatory markers in normoglycemia, IGT, IFG, and undiagnosed diabetes in 
5,109 ARIC Dental Study participants without diagnosed diabetes is displayed in 
Table 7, with all inflammatory markers showing no statistically significant 
associations with glycemic status (all P-values were >0.05). 
 
 34 
 In the analysis of 2 hr GTT (Table 8), severe clinical periodontal 
inflammation (Category V) was associated with elevated risk of impaired glucose 
tolerance in an unadjusted model with an odds ratio of 1.3 (95% CI: 1.0-1.7).  
However after adjustment for lifestyle and co-morbidity variables, this association 
attenuated to null. (OR=1.0, 95% CI: 0.7-1.3).  
 
As Shown in Table 9, compared to individuals in Category I, participants 
with more severe periodontal clinical inflammation had increased odds of 
impaired fasting glucose. Compared to individuals in Category I, the odds ratio 
for impaired fasting glucose in Category V was 2.1 (95% CI: 1.6-2.8) in an 
unadjusted model. This relationship remained in the fully adjusted model with an 
odds ratio of 1.5 (95% CI: 1.1--2.1) in the highest category of one or more sites 
with a probing depth >4 mm and bleeding upon probing 50%.  
 
Results in the undiagnosed diabetics mirrored the findings in the IFG 
groups, showing that severe clinical periodontal inflammation was associated 
with undiagnosed diabetes after adjusting for all covariates. (OR=1.5, 95% CI: 
1.0-2.2).  (Table 10) 
 
To further explore the relationship, between prediabetes and periodontal 
inflammation, we performed four additional analyses using markers of systemic 
inflammation (serum antibody levels to the periodontal pathogens 
Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans), and 
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markers of localized inflammation (gingival crevicular fluid levels of IL-1 (GCF- 
IL-1) and gingival crevicular fluid levels of prostaglandin (PG-E2) (Tables 11-
13). However, no significant association was observed between pre-diabetes or 
undiagnosed diabetes and any of those inflammation markers.  
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Table 4-Baseline characteristics of 6,138 middle-aged adults with 
















2,154 1,572 1307 1105  
Male sex (%) 61.8  62.0 58.5 57.6 <0.0001 
Age (years) 61.55.6 63.35.6 61.35.6 62.85.4 <0.0001 
African 
American (%) 








12.70.3 10.10.3 14.90.4 12.70.3 0.0082 




1,578652 1,587603 1,637673 1,608690 0.1253 
Body mass 
index (kg/m2) 




95.912.6 102.513.6 102.613.2 103.714.2 <0.0001 
Hypertension 
(%) 












1.40.5 1.30.4 1.20.4 1.30.3 <0.0001 
Characteristics are statistically different if p<0.05 using ANOVA tests for continuous variables and 
2 for categorical variables 
Data are mean  SD or percent. 
Normal glucose=FG<100mg/dL & 2hrGTT<140mg/dL & no diabetes 
Impaired Glucose Tolerance=2hr glucose of140-199mg/dL & no diabetes 
Impaired fasting glucose=FG of 100-125mg/dL & 2hr GTT<140mg/dL & no diabetes  
Undiagnosed diabetes=FG>125mg/dL, or 2hr GTT>199mg/dL & no diabetes diagnosis 
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Table 5-Baseline characteristics of 6,138 Visit 4 participants receiving 
dental examinations excluding diagnosed diabetic subjects. 










































Age (years) 62.25.6 62.35.6 62.45.5 62.35.6 62.75.4 0.3393 
African 
American (%) 










10.70.3 8.50.3 14.40.4 12.20.3 17.60.3 <0.000
1 





















































































Characteristics are statistically different if p<0.05 (ANOVA tests for continuous variables and 2 
for categorical variables), Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference 
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category),Category II=probing depth (PD) 3mm, bleeding upon probing >10%, Category III=one or more 
sites with PD4mm, bleeding upon probing 10%,Category IV=one or more sites with PD4mm, bleeding 
upon probing >10% and <50%,Category V=one or more sites with PD4mm, bleeding upon probing 50. 
Data are mean  SD or percent.   
Table 6-Prevalence(%) with normal glycemia, IGT, IFG, and undiagnosed 
diabetes by clinical category in 6, 138 ARIC Dental Study participants 
 N Category 












































P-value was P<0.0001 using a 2 test 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing  >10% and <50% 
Category V=one or more sites with PD4mm, bleeding upon probing 50% 
 
Normal glucose=FG<100mg/dL & 2hrGTT<140mg/dL & no diabetes 
Impaired Glucose Tolerance=2hr glucose of140-199mg/dL & no diabetes 
Impaired fasting glucose=FG of 100-125mg/dL & 2hr GTT<140mg/dL & no diabetes  






Table 7- Prevalence (%) of normoglycemia, IGT, IFG, and undiagnosed 
diabetes by inflammatory marker in 5,109 ARIC Dental Study participants 















  High Low High Low High Low High Low 
Normal 4054 6.6 93.4 5.0 95.0 3.5 97.5 6.6 93.4 
IGT 620 8.1 91.9 5.6 94.4 3.7 96.2 7.0 93.0 
FG 314 7.8 92.2 4.8 95.2 3.5 97.5 5.7 94.3 
Undiagnosed 121 5.7 94.3 4.9 95.1 3.7 96.2 5.4 94.6 
P- value  0.45  0.34  0.09  0.59  
All P-values used 2 tests for each inflammatory marker 
Normal glucose=FG<100mg/dL & 2hrGTT<140mg/dL & no diabetes  
Impaired Glucose Tolerance=2hr glucose of140-199mg/dL & no diabetes 
Impaired fasting glucose=FG of 100-125mg/dL & 2hr GTT<140mg/dL & no diabetes  
Undiagnosed diabetes=FG>125mg/dL, or 2hr GTT>199mg/dL & no diabetes diagnosis  
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 
High GCF- IL-1 levels at 146ng/mL (highest quartile) 
High GCF PG-E2 levels 239ng/mL (highest quartile) 







Table 8- Odds ratios for Impaired Glucose Tolerance in 6, 138 ARIC Dental 





























































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, CHD, 
family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing>10% and <50% 





Table 9- Odds ratios for Impaired Fasting Glucose in 6, 138 ARIC Dental 
Study participants without diagnosed diabetes by Category of Clinical 
Periodontal Inflammation 























































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, 
CHD, family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10 and <50% 



















Table- 10-Odds ratios for undiagnosed diabetes in 6, 138 ARIC Dental 
Study participants without diagnosed diabetes by Category of Clinical 
Periodontal Inflammation 














































1.7     
(1.2-2.4) 










Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, CHD, 
family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10% and <50% 







Table 11- Odds ratios for impaired Glucose in 5,109 ARIC Dental Study 
participants without diagnosed diabetes by Inflammatory Markers for 
Periodontal Inflammation 
 Antibody to P. 
gingivalis (high 
vs. low) 
Antibody to A.a. 
(high vs. low) 
GCF levels of IL-
1 
(high vs. low) 
GCF levels of 
PG-E2 
(high vs. low) 












































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, CHD, 
family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10% and <50% 
Category V=one or more sites with PD4mm, bleeding upon probing 50% 
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 
High GCF- IL-1 levels at 146ng/mL (highest quartile) 
High GCF PG-E2 levels 239ng/mL (highest quartile) 

























Table 12- Odds ratios for Impaired Fasting Glucose in 5,109 ARIC Dental 
Study participants without diagnosed diabetes by Systemic Markers for 
Periodontal Inflammation 
 Antibody to P. 
gingivalis 
(high vs. low) 
Antibody to A.a. 
(high vs. low) 
GCF levels of IL-
1 
(high vs. low) 
GCF levels of 
PG-E2 
(high vs. low) 












































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, CHD, 
family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10% and <50% 
Category V=one or more sites with PD4mm, bleeding upon probing 50% 
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 
High GCF- IL-1 levels at 146ng/mL (highest quartile) 
High GCF PG-E2 levels 239ng/mL (highest quartile) 






















Table 13- Odds ratios for Undiagnosed Diabetes by Systemic Markers for 
Periodontal Inflammation 
 Antibody to P. 
gingivalis  
(high vs. low) 
Antibody to A.a. 
(high vs. low) 
GCF levels of IL-
1 
(high vs. low) 
GCF levels of 
PG-E2 
(high vs. low) 








































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, waist circumference, sports index, CHD, 
family history diabetes, hypertension, cholesterol, total caloric intake) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10% and <50% 
Category V=one or more sites with PD4mm, bleeding upon probing 50% 
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 
High GCF- IL-1 levels at 146ng/mL (highest quartile) 
High GCF PG-E2 levels 239ng/mL (highest quartile) 



















 In this cross- sectional analysis, we found clinical periodontal measures 
for inflammation were associated with the likelihood of impaired fasting glucose. 
This association seemed to hold true for individuals with only slight bleeding 
upon probing, with deeper probing measurements, or more severe gingival 
bleeding upon probing. However, a dose response relationship was not observed 
with increasing severity of periodontal inflammation. These results were 
consistent with the clinical implications since probing depths give a measure of 
prior periodontal attachment loss, while bleeding upon probing assesses current 
inflammation. A periodontal exam that combines probing depth and bleeding 
scores gives an accurate assessment of prior and current periodontal status, and 
both are used together in the examination and diagnosis of dental patients in the 
clinical setting.  
 
 The association for clinical periodontal inflammation may even appear 
mildly protective for undiagnosed diabetics in Category III periodontitis, though 
this association did not appear significant (OR=0.9, 95 % CI: 0.6-1.3). This may 
be explained by the means of assessment of inflammation, since even though 
the probing depth has increased when comparing Categories III to I, the bleeding 
score is the same from both groups (10% bleeding upon probing is assigned for 
both categories).  Bleeding upon probing may give a better picture in the biologic 
pathway of active, or current periodontal inflammation. Probing measurements 
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represent attachment loss from prior periodontal disease exposure, thus giving a 
clinical picture of past history of lost supporting periodontal tissues including 
bone and periodontal ligament fibers around remaining teeth. No information 
regarding current or prior periodontal treatment was available in this dataset, 
which may have helped to explain active versus prior periodontal inflammation. 
 
 A subsidiary analysis of baseline characteristics of 4, 864 individuals 
available at visit 4, but excluded from the periodontal examination, was 
performed (results not shown). The individuals excluded from our primary 
analysis had a higher proportion of African-Americans (39% vs. 24%), smokers 
(19% vs. 13%), increased caloric intake (1773 kcal/day vs. 1587kcal/day) and 
higher body mass-indices (31kg/m2 vs. 28.9kg/m2). These aforementioned 
characteristics are known risk factors for diabetes. It is possible that exclusion of 
these individuals from the analysis may have resulted in an underestimated risk 
of pre-diabetes. Additionally, 15 % (n=1,478) of the visit 4 participants were 
edentulous. If we assume that tooth loss is a surrogate for severe periodontal 
disease status, then it is possible a large proportion of individuals with prior 
exposure to severe periodontal inflammation were not available for analysis, also 
resulting in an underestimated risk of pre-diabetes.  
 
 A stronger association of periodontal disease with fasting glucose than 
with glucose tolerance tests was observed. This may be explained by the less 
than 100% concordance rate between these two tests.49 In clinical practice, when 
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there is disparity between the test, the test whose result is higher should be 
repeated.49 Repeat tests results for confirmation of classification of diabetic 
status were not available in this ARIC dataset. 
     
 This study is novel by combining both clinical and systemic measures 
specific to periodontal inflammation to correlate with pre-diabetes. This approach 
was used to assess cardiovascular disease as an outcome.54 However, unlike in 
those cardiovascular studies, our study did not show a significant association 
between systemic inflammatory mediators and pre-diabetes. Our study 
suggested that the association of periodontal inflammation with pre-diabetes  
was not the same as the association with the risk of cardiovascular disease.50, 51 
It indicated that the biologic pathway of periodontal inflammation is different when 
comparing impaired glucose tolerance and prediabetes with cardiovascular 
disease.  While serum antibodies levels to periodontal pathogens 
Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans can show 
prior exposure to periodontal inflammation, these levels did not show an 
association with impaired glucose, elevated fasting glucose, or undiagnosed 
diabetes in our fully adjusted models.  
 
While IL-1 and PG-E2 levels have been shown to be elevated in 
presence of both periodontal disease and diabetes in other studies, our data did 
not show this association. The few mechanistic studies looking at markers for 
inflammation common to the pathogenesis of periodontal disease and diabetic 
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status, included type 2 diabetic patients in very small studies to conclude that IL-
1 may be associated with both diseases. 26,43,44 Inclusion of individuals with 
diabetes may significantly alter the inflammatory profile, and those studies may 
have displayed reverse causality, where diabetes, not periodontal disease, 
increased inflammatory marker levels. Even though we excluded type 2 diabetes 
individuals from our data set, our sample size of 5109 subjects with laboratory 
assays still consisted of a large number of individuals for analysis.  While clear 
association could not be seen with IL-1 and PG-E2 levels in gingival crevicular 
fluid with impaired glucose levels, our study indicated additional inflammatory 
markers might need to be examined to better understand this association. A 
more complex, or non-linear association may be possible, as expected with other 
inflammatory mediators. 
 
By excluding individuals with diagnosed diabetes in the cross sectional 
analysis, we reduce the possibility of reverse causality of diabetes causing 
periodontal inflammation Unlike the majority of previous studies that looked at the 
association of periodontal disease with diabetes, this study is strengthened by 
leaving this group out, in order to see if pre-diabetes status is associated with 
periodontal inflammation. Individuals with diabetes also have widespread 
systemic abnormalities in the immune response, which can create an over-




The serum levels for inflammatory mediators used the highest quartile to 
define high vs. low levels, as in other studies that assessed the association of 
periodontal disease with cardiovascular disease risk.51 It is possible that the 
highest quartile may represent a unique population with the possibility for 
residual confounding. This study used a similar cut-point, thus may have 
overestimated the association of periodontal inflammation with pre-diabetes. 
Additionally, genetic risk factors known to affect diabetic status were not 
available in this dataset, and were not included in these models. 
 
The potential for selection bias exists, since not all Visit 4 participants 
were included in the analysis. It is possible that the 15% (n=1,748) of edentulous 
participants excluded from this analysis had a history of the most advanced 
periodontal status, with resulting prior tooth loss and subsequent edentulism. 
This study is not generalizable to individuals missing all their dentition. The 
periodontal status of the 13% (N=1,515) that refused the dental exam remains 
unknown.  
  Using one time measure of fasting glucose may not be reliable. Repeat 
test results for confirmation of classification of diabetic status is recommended in 









This study suggested clinical periodontal inflammation was cross-
sectionally associated with impaired fasting glucose.  An increase in bleeding 
upon probing appears to be cross-sectionally associated with impaired fasting 
glucose. Since even minimal bleeding upon probing in this study was associated 
with prevalent pre-diabetes and undiagnosed diabetes, a strong case may be 
made to support patient education for prevention of periodontal disease and 
study the effect of prevention of even mild periodontal inflammation on 
prediabetes and diabetes.   
 
With an association of clinical measures of periodontal inflammation with 
pre-diabetes, an assessment of risk of impaired fasting glucose may be 
performed easily in the dental office. This requires a dental exam commonly and 
currently performed by dental providers. The use of immunoassays, which are 
costly, and technically demanding, may not be necessary to define the 
relationship of periodontal disease with pre-diabetes.   
 
Presumably, the prevention of gingival inflammation may moderately 
reduce the risk of diabetes onset. The reduction of periodontal disease, and then 
diabetes, has potential to slow the growing epidemic proportions of both 
diseases. This study contributes to the sparse evidence for the association of 
periodontal association with pre-diabetes. 
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Chapter 3 
The prospective association of periodontal 
disease and the risk of type 2 diabetes 
Abstract 
 
Though the bi-directionality of periodontal disease and diabetes is widely 
discussed, evidence of periodontal disease and subsequent risk of diabetes is 
sparse. Using data from the Atherosclerosis Risk in Communities (ARIC) Study, 
we tested the hypothesis that exposure to periodontal inflammation, using clinical 
exam evidence, systemic inflammatory markers and local inflammatory markers, 
predicts the subsequent occurrence of incident type 2 diabetes. Of the total 5,819 
eligible participants at baseline (ARIC Visit 4), 1,967 individuals developed 
incident type 2 diabetes after a mean of 13.8 years of follow-up.  Incident 
diabetes was assessed with yearly telephone interviews and self-reports form 
study participants. 
 
In multivariable analyses using the Cox proportional hazards model, when 
compared to Category I (probing depth (PD) 3mm, bleeding upon probing 
10%), the hazard ratio of incident diabetes was the highest with early 
periodontal clinical measures of inflammation as found in Category II (probing 
depth (PD) 3mm, bleeding upon probing >10%) (HR=1.4, 95%CI: 1.1-
1.7,p<0.001) after adjustment for sex, age, race, education level, smoking status, 
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physical activity, total caloric intake, waist circumference, hypertension, previous 
cardiovascular disease, family history of diabetes, and HDL cholesterol levels. 
Compared with individuals in Category I, with minimal bleeding and probing 
measures, the hazard of incident diabetes appears to be 1.2 times higher (95% 
CI: 1.0 – 1.4, p<0.001) in adults with moderate clinical periodontal inflammation 
(Category IV-one or more sites with PD4mm, bleeding upon probing >10% 
&<50%) and 1.3 times higher (95% CI: 1.0- 1.6, P<0.001) in adults with 
advanced clinical periodontal inflammation (Category V- one or more sites with 
PD4mm, bleeding upon probing 50%). This data supports the hypothesis that 




A two-way relationship between type 2 diabetes and periodontal disease 
has been discussed in the literature, as a clear association between 
hyperglycemia and severity of periodontal disease has been shown. 52 The 
mechanism of this relationship has not been completely understood, but 
physiological models propose an immunologic response, and inflammation 
appears common to the pathogenesis of both diseases.19 Evidence to help define 
the directionality of periodontal disease and risk of type 2 diabetes are important 
to understand possible mechanisms common to both diseases. Such studies are 
lacking in the literature, despite discussion of the bidirectional relationship for 
almost the past 20 years. While a preponderance of literature shows the effect of 
diabetes on periodontal inflammation, the evidence supporting the effect of 
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periodontal disease on the risk of incident diabetes is lacking. The consensus 
report from the Joint European Federation of Peridontology and the American 
Academy of Periodontology recommended longitudinal designs, large cohorts, 
and inclusion of clinical and immunologic biomarkers to help define the impact of 
periodontal inflammation on incident diabetes.53 
 
 Systemic inflammation has emerged as a risk factor for type 2 diabetes, 
but the contribution of periodontal inflammation to diabetes onset is unknown.  
Both diabetes and periodontal disease have been found to result in an elevation 
of inflammatory cytokines as a host response.  Gram-negative bacteria found in 
periodontal disease have been found to result in elevated levels of these 
cytokines, such as Prostaglandin E2 (PGE2) in both the gingival crevicular fluid 
and in peripheral blood in individuals with diabetes and periodontal disease. 
Those with diabetes and advanced periodontal disease had two-fold higher 
levels of PGE2   and Interleukin-, 1β (IL- 1β) when compared to those with 
diabetes and milder forms of periodontal disease. 27 
 
Evidence to help define the directionality of periodontal disease and risk of 
type 2 diabetes are important to understand possible mechanisms common to 
both diseases. Such studies are lacking in the literature, despite discussion of the 
bidirectional relationship for almost the past 20 years. We hypothesized that 
exposure to periodontal inflammation, (using clinical exam evidence, systemic 
inflammatory markers and local inflammatory markers), predicts the subsequent 
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occurrence of incident type 2 diabetes.  Our study uniquely looks at 
comprehensive clinical measures of periodontal inflammation (bleeding upon 
probing and full mouth probing depths), systemic markers for prior exposure to 
periodontal inflammation (serum antibodies to the periodontal pathogens 
(Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans), and 
local biomarkers for periodontal inflammation (gingival crevicular fluid levels of IL-
1 and PG-E2) in a cohort followed for approximately 14 years to assess 






The Atherosclerosis Risk in Communities (ARIC) Study is a community-
based prospective cohort of 15,792 middle-aged adults from four U.S. 
communities. The first examination of participants (Visit 1) took place during 
1987–1989, with three follow-up visits taking place: each approximately every 3 
years. The Dental ARIC study, an ancillary study, funded by the National Institute 
of Dental and Craniofacial Research (NIDCR), was conducted during ARIC Visit 
4 in 1996 through 1998 and is cross-sectional in design. The Dental ARIC 
consisted of an oral examination, collection of serum, and interviews.  Of those 
15, 792 ARIC cohort members examined at baseline (1987 to 1989), responders 
to a dental screening interview were selected. Respondents with no teeth or a 
medical contraindication to probing were excluded, while some refused the 
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dental exam. In addition, participants with type 2 diabetes, missing demographic 
data, missing serum samples, and unreadable samples were excluded. The final 
analysis included data from 5109 participants. (Figure 4 in Chapter 2 showed the 
participants available at baseline for this analysis,) 
Periodontal Disease 
 
Clinical assessments of periodontal inflammation were defined by two 
assessments: bleeding upon probing and periodontal pockets (rounded down to 
the nearest mm). This definition is consistent with the standard of care in 
assessing the clinical periodontal status. (See Appendix- Figure 17)  Using 
these two parameters, participants were classified into 5 categories: 46 
 
I) probing depth (PD) 3mm, bleeding upon probing 10% 
II) probing depth (PD) 3mm, bleeding upon probing >10% 
Iii) one or more sites with PD4mm, bleeding upon probing 10% 
IV) one or more sites with PD4mm, bleeding upon probing>10% &<50% 
V) one or more sites with PD4mm, bleeding upon probing 50% 
 
Serum markers of prior periodontal disease exposure were defined by 
serum IgG antibodies to the periodontal pathogens Porphyromonas gingivalis 
and serum IgG antibodies to Actinobacillus actinmycetemcommitans. These 
variables were measured as the level of antibody response to the periodontal 
pathogen Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans 
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in Elisa units (EU). Using the upper quartile as the cut-point, the high antibody 
group was compared to the low antibody group (lower three quartiles). 
Porphyromonas gingivalis antibody levels were considered high at 78.93 EU, 
and Actinobacillus actinmycetemcommitans antibody levels were considered 
high at 144 EU. The use of the upper quartile for assigning the high antibody 
level group has been used on other studies.51 The normal antibody level in 
periodontal health for these periodontal pathogens has not yet been established.  
 
Local inflammatory markers of periodontal disease were assessed using 
gingival crevicular fluid levels of IL-1 (GCF- IL-1) and gingival crevicular fluid 
levels of prostaglandin (PG-E2). The variable GCF- IL-1 was measured as the 
level of gingival crevicular fluid units (ng/mL). Using the upper quartile as the cut-
point, subjects were considered to have high levels of GCF- IL-1 levels at 
146ng/mL. The variable PG-E2 was also measured as the level of gingival 
crevicular fluid units (ng/mL) and a dichotomous variable (high/low) was used. 
Subjects were considered to have elevated levels of PG-E2 levels at 239ng/mL 
using the upper quartile cut-point. Similarly to the antibody levels to P.g and A.a, 
normal levels of IL-1 and PG-E2 in periodontal health have not been 
established.   
 All clinical periodontal measures, as well as serum and gingival crevicular 
samples were measured at VIsit 4 (1996 through 1998). 
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Prevalent Type 2 Diabetes 
  
The ARIC visit 4 individuals were classified as having a diabetes diagnosis 
if any of the following criteria were met; self- report of current use of medication 
for diabetes of blood sugar; or a positive response to the question “Has a doctor 
ever told you that you had diabetes (sugar in the blood)?”. Undiagnosed diabetic 
individuals were classified as having fasting glucose of at least 7.0mmol/L 
(126mg/dL); non-fasting glucose of at least 11.1mmol/L (200mg/dL), but no 
doctor diagnosis of diabetes and no self-report of anti-diabetic medication. These 
ARIC definitions were based on the 1997 American Diabetes Association criteria 
available at the time of the ARIC Visit 4. 
 
Incident Type 2 Diabetes  
 
 Individuals from baseline Visit 4 were telephoned yearly and were 
classified as having diabetes if answering positive to either current use of anti-
diabetic medication or having been “told by a doctor that they have diabetes or 
sugar in the blood”. Persons classified as having diabetes at baseline were 
excluded. This dataset includes self-reports that were obtained until the end date 





Covariates measured at the visit 4 baseline included sex, age, race, 
education, smoking, physical activity, total caloric intake, BMI, waist 
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circumference, hypertension, previous cardiovascular disease, family history of 
diabetes, and high density lipoprotein levels.  Information on age, sex, race, 
smoking, total caloric intake, education level and family history of diabetes were 
based on self –report. BMI (weight in kilograms divided by the square height in 
meters) and waist to hip ratio (in centimeters) were measured with standard 
procedures.47 Prevalent cardiovascular disease was based on self-report, ARIC 
clinical exam, or hospital records. The physical activity was assessed using a 
modified version of the questionnaire developed by Baecke and colleagues, from 
which a sport index was derived, ranging from 1 (lowest) to 5 (highest).48 HDL 
cholesterol levels were measured after dextran-magnesium precipitation. The 
education levels, however were measured earlier, at visit 1 (1978-1989), and 





 All subjects with diagnosed or undiagnosed diabetes at the baseline (visit 
4) were excluded. Therefore, 5109 participants were included in the final 
analysis.  Individuals from baseline visit 4 were telephoned yearly and were 
classified as having diabetes if answering positive to either current use of anti-
diabetic medication or having been “told by a doctor that they have diabetes or 
sugar in the blood”.  For participants without diabetes, study time was calculated 
from baseline Visit 4 to the last follow-up date. Individuals who died were 
censored at the date of death. 
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Baseline characteristics of participants were described using means and 
frequencies of each potential confounder for each category of clinical periodontal 
inflammation (Category I-V- Table 14). ANOVA and 2 analyses were used to 
assess the statistical differences across the 5 categories.  Similar descriptive 
statistics were also performed for 3 categories of bleeding upon probing  
(mild BOP= bleeding upon probing 10% (reference category), moderate BOP= 
bleeding upon probing 11-49%, Severe BOP= bleeding upon probing 50%) 
(Table 15).  
 
To explore the relationship between periodontal disease and incident 
diabetes, five models were constructed to adjust for demographic variables (sex, 
age, race, and education), lifestyle covariates (physical activity), waist 
circumference, and medical history (cardiovascular disease, family history of 
diabetes, hypertension, high density lipoprotein levels, and total caloric intake).                                
  
Time to incident diabetes was assessed over a mean of 13.84 years of 
follow-up. Kaplan-Meier survival analysis curves were plotted and incidence rates 
(1000 person-years) were calculated for periodontal disease (Categories I-V), 
antibody levels to the pathogens Porphyromonas gingivalis and Actinobacillus 
actinmycetemcommitans, and serum gingival crevicular fluid levels of IL-1 
(GCF- IL-1) and prostaglandin (PG-E2). Log-rank tests were performed for 
categories of periodontal disease (I-V) and for categories of bleeding upon 
probing (mild/moderate/severe). Cox proportional hazards models were used in 
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the multivariable analysis with a proportionality assumption implicit in adjusted 
models. Relative hazard ratios were used to compare the risk of diabetes in the 
subjects with increased clinical periodontal measures (Category II-V) versus the 
group with minimal bleeding upon probing and shallow probing measurements 
(Category I). Relative hazard ratios were used to compare the risk of incident 
diabetes in the high versus low levels of serum antibody levels to the periodontal 
pathogens Porphyromonas gingivalis and Actinobacillus 
actinmycetemcommitans) and high versus low levels of serum gingival crevicular 
fluid levels of IL-1 (GCF- IL-1) and prostaglandin (PG-E2). Missing data and 
participants positive for type 2 diabetes at baseline were excluded in each 
analysis. All tests of significance were two–tailed, with an  level of 0.05. All 




Baseline characteristics by clinical periodontal inflammation status 
(category I-V) were presented in Table 14. All the characteristics were 
considered statistically different between the groups if p<0.05. The categories 
with more severe clinical inflammation were more likely to be female, smokers, 
and less physically active. These periodontal groups also display higher caloric 
intake, BMI, waist circumference, hypertension, HDL cholesterol, fasting glucose 
and 2 hr glucose tolerance levels. (P<0.0001) There were no differences in age 
(P=0.158), previous history of cardiovascular disease (P=0.159), and family 
history of diabetes (P=0.071). A subsidiary analysis of baseline characteristics of 
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4, 864 individuals available at visit 4, but excluded from the periodontal 
examination, was performed (results not shown). The individuals excluded from 
our primary analysis had a higher proportion of African-Americans (39% vs. 
24%), smokers (19% vs. 13%), increased caloric intake (1773 kcal/day vs. 
1587kcal/day) and higher body mass-indices (31kg/m2 vs. 28.9kg/m2 ).  
 
Baseline characteristics by category of bleeding upon probing status were 
presented in Table 15.  The characteristics were considered statistically different 
between the groups if p<0.05. The categories with more severe bleeding upon 
probing (50% of sites) were more likely to be female, smokers, and less 
physically active. These periodontal groups also display higher caloric intake, 
BMI, waist circumference, hypertension, HDL cholesterol, previous history of 
cardiovascular disease, family history of diabetes. fasting glucose and 2 hr 
glucose tolerance levels. (P<0.0001) There were no differences in age (P=0.20 ) 
among these three groups. 
 
During 13.84 years of follow up, 1,967 individuals developed Type 2 
diabetes of the total (n= 5,819) participants. Missing data and participants 
positive for type 2 diabetes at baseline were excluded in each analysis. The 
incidence rate of diabetes with a healthy periodontal status was 17.4. per 1000 
person-years (95%CI: 17.2-19.0), while the incidence rates for Category II and V 
clinical inflammation were significantly higher at 22.3 (95%CI: 20.9-23.7) and 
23.9 (95%CI: 22.2-25.2) per 1000 person-years, respectively (p<0.001).  (Table 
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16)  The incidence of type 2 diabetes did not appear to increase monotonically 
across the 5 periodontal categories. 
Kaplan-Meier analysis (Figure 5) and the associated log-rank tests, 
showed that the early and severe periodontal disease (Category II-(probing depth 
(PD) 3mm, bleeding upon probing >10%, and Category V- one or more sites 
with PD4mm, bleeding upon probing 50%),  had higher cumulative diabetes 
incidence (P<0.0001), than the reference group ( Category I=probing depth (PD) 
3mm, bleeding upon probing 10% ), Category III (one or more sites with 
PD4mm, bleeding upon probing 10%) and Category IV (one or more sites with 
PD4mm, bleeding upon probing >10% and<50%) (p<0.0001, Figure 5). No 
differences in incident diabetes could be seen in the KM-plots of antibody levels 
(high vs. low) to the pathogens Porphyromonas gingivalis and Actinobacillus 
actinmycetemcommitans, and serum gingival crevicular fluid levels of IL-1 
(GCF- IL-1) and prostaglandin (PG-E2) (P>0.05, Figures 6-9).  
 In multivariable analyses, for the diabetes cases using the Cox 
proportional hazards model, the hazard ratio appeared the highest with early 
periodontal clinical measures of inflammation as found in Category II (1.4, 
95%CI: 1.1-1.7p<0.001) after adjustment for sex, age, race, education level, 
smoking status, physical activity, total caloric intake, waist circumference, 
hypertension, previous cardiovascular disease, family history of diabetes, and 
HDL cholesterol levels. (Table 16) Compared with individuals with minimal 
bleeding and probing measures, the hazard of incident diabetes appears to be 
1.2 times higher in adults with moderate (Category IV) (95%CI: 1.0-1.4, P<0.001) 
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clinical periodontal inflammation and 1.3 times higher in adults with advanced 
periodontal inflammation (Category V) (95%CI: 1.0-1.6, P<0.001). However 
Category III did not display this increasing significant trend with a hazard ratio of 
1.0 (95% CI: 0.8-1.20). As expected, additional adjustment including fasting 
glucose (model 6) or 2-hr GTT (model 7) further attenuated the association, 
because they were both in the causal pathway. A dose-response relationship 
with clinical inflammation could be seen by using only bleeding upon probing as a 
measure for clinical inflammation. (Table 17). Censoring of individuals who died 
during follow-up (n= 211) also did not change the associations observed with 
incident diabetes (data not shown). 
 
 To investigate the relationship of incident diabetes to other inflammatory 
measures of periodontal disease exposure, additional analyses including 
participants with assays of periodontal inflammation were performed.  First, to 
determine if systemic markers specific to exposure to periodontal inflammation 
might help explain the relationship of periodontal disease to diabetes risk, 
antibodies to the periodontal pathogens Porphyromonas gingivalis and 
Actinobacillus actinmycetemcommitans were included into multivariable models 
adjusted for age, sex, race, smoking, waist circumference, cardiovascular 
disease, family history of diabetes, total caloric intake, and cholesterol levels. 
The hazard of incident diabetes appeared no different in adults with high levels of 
antibodies to Porphyromonas gingivalis compared to low serum levels. The 
hazard ratios for antibodies to Actinobacillus actinmycetemcommitans also 
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appeared to be in these ranges but did not reach statistical significance. (Table 
18) 
 
  Data on localized markers for periodontal inflammation were available, 
and additional adjusted multivariable analyses using gingival crevicular fluid were 
performed. High levels of gingival crevicular fluid IL-1 were associated with no 
change in hazard of incident diabetes (HR=1.0, CI:0.8-1.2).  High levels of1 PG-
E2 were also associated with no increased hazard of incident diabetes (1.0: 95% 
















Table 14- Baseline Characteristics of 5, 819 Visit 4 participants receiving 
dental examinations excluding diagnosed and undiagnosed subjects with 
















860 861 1,084 2,326 688  
Male sex (%) 73.4 64.2 53.0 50.8 40.3 <0.0001 
Age (years) 62.25.5 62.35.8 62.45.6 62.35.6 62.75.8 0.198 
African 
American (%) 








10.60.3 8.60.3 14.40.4 12.40.3 18.10.4 <0.0001 




1548668 1556595 1564574 1627634 1739786 <0.0001 
Body mass 
index (kg/m2) 




101.914.6 104.514.3 102.612.7 103.813.5 10713.9 <0.0001 
Hypertension 
(%) 























134.440 123.040 130.341 132.340 <0.0001 
Characteristics were statistically different if p<0.05 using ANOVA tests for continuous variables 
and 2 for categorical variables 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category), Category 
II=probing depth (PD) 3mm, bleeding upon probing >10%, Category III=one or more sites with PD4mm, 
bleeding upon probing 10%, Category IV=one or more sites with PD4mm, bleeding upon probing >10% 
and <50%, Category V=one or more sites with PD4mm, bleeding upon probing 50% 
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Table 15-Baseline Characteristics of 5, 819 Visit 4 participants receiving 
dental examinations excluding subjects with diagnosed and undiagnosed 
diabetes 



























Age (years) 62.35.5 62.35.6 62.85.8 0.1979 
African American (%) 17.9  12.9 29.8 <0.0001 
Education <=12 Years (%) 53.9 48.3 63.6 <0.0001 
Smoking Status (%)-Current 12.7 11.2 17.8 <0.0001 
Sports Index 2.60.8 2.50.8 2.40.8 <0.0001 
Total Calorie Intake (Kcal/day) 1556617 1596620 1731776 <0.0001 
Body mass index (kg/m2) 27.75.0 28.25.1 29.05.6 <0.0001 
Waist Circumference (cm) 98.213.6 100.413.7 102.714.1 <0.0001 
Hypertension (%) 38.0 39.5 48.8 <0.0001 
Previous Cardiovascular 
Disease (%) 
5.2 5.0 6.8 <0.0001 
Family History of Diabetes (%) 12 12 13 <0.0001 












Total Calorie Intake (Kcal/day) 1556617 1596620 1731776 <0.0001 
Mean Fasting Glucose (mg/dL) 98.09.2 98.99.3 101.39.4 <0.0001 











Characteristics were statistically different if p<0.05, using ANOVA tests for continuous variables 
and 2 for categorical variables 
Mild BOP= bleeding upon probing 10% (reference category) 
Moderate BOP= bleeding upon probing 10-49% 















Table 16- Relative Hazard of Type 2 Diabetes over 13.8 years follow-up by 
Category of Clinical Periodontal Inflammation 




























































































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates (sex, age, race, education, physical activity, smoking total caloric 
intake) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully (for sex, age race, education, smoking, total caloric intake, waist circumference, sports index, 
CHD, family history diabetes, hypertension, cholesterol)  
Model 6- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus 2-hour glucose tolerance test 
level (continuous variable) 
Model 7- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus fasting glucose (continuous 
variable) 
Category I=probing depth (PD) 3mm, bleeding upon probing 10% (reference category) 
Category II=probing depth (PD) 3mm, bleeding upon probing >10% 
Category III=one or more sites with PD4mm, bleeding upon probing 10% 
Category IV=one or more sites with PD4mm, bleeding upon probing >10% and <50% 










Table 17-Relative Hazard of Type 2 Diabetes over 13.7 years follow-up by 
Category of  Clinical Bleeding Upon Probing 





















































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity, smoking total caloric 
intake) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) 
Model 6- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus 2-hour glucose tolerance test 
level (continuous variable) 
Model 7- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus fasting glucose (continuous 
variable) 
Mild BOP= bleeding upon probing 10% (reference category) 
Moderate BOP= bleeding upon probing 10-49% 
















Table 18- Relative Hazard of Type 2 Diabetes over 13.7 years follow-up by 
Systemic Markers for Periodontal Inflammation 
  Antibody to P. 
gingivalis (high 
vs. low) 
Antibody to A.a. 
(high vs. low) 
GCF levels of 
IL-1 
(high vs. low) 
GCF levels of 
PG-E2 









































































Model 1- unadjusted 
Model 2- adjusted for sex, age, race, and education 
Model 3- adjusted for lifestyle covariates –(sex, age, race, education, physical activity, smoking, total caloric 
intake) 
Model 4-adjusted for lifestyle covariates and waist circumference  
Model 5- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) 
Model 6- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus 2-hour glucose tolerance test 
level (continuous variable) 
Model 7- fully adjusted (for sex, age race, education, smoking, total caloric intake, waist circumference, 
sports index, CHD, family history diabetes, hypertension, cholesterol) plus fasting glucose (continuous 
variable) 
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 
High GCF- IL-1 levels at 146ng/mL (highest quartile) 
High GCF PG-E2 levels 239ng/mL (highest quartile) 


















Figure 4: - Cumulative probability of incident type 2 diabetes over 13.8 
years follow-up by category of clinical periodontal inflammation 
 













Figure 6:Cumulative probability of incident type 2 diabetes over 13.8 years 
follow-up by serum antibody levels to Porphyromonas gingivalis 
 
Follow-up Time (Years) 
 
 
Log-rank test p>0.05  
High Porphyromonas gingivalis antibody levels at 78.93 EU (highest quartile) 
Low Porphyromonas gingivalis antibody levels at <78.93 EU (lower three quartiles)
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Figure 7: Cumulative probability of incident type 2 diabetes over 13.8 years 
follow-up by serum antibody levels to Actinobacillus 
actinmycetemcommitans 
 




Log-rank test p>0.05  
High Actinobacillus actinmycetemcommitans antibody levels 144 EU (highest quartile) 











Figure 8:Cumulative probability of incident type 2 diabetes over 13.8 years 
follow-up by  
GCF levels of IL-1 
 
 
Follow-up Time (Years) 
 
 
Log-rank test p>0.05  
High GCF- IL-1 levels at 146ng/mL (highest quartile) 



















Figure 9:Cumulative probability of incident type 2 diabetes over 13.8 years 
follow-up by GCF levels of PG-E2 
 




Log-rank test p>0.05  
High GCF PG-E2 levels 239ng/mL (highest quartile) 












 In a longitudinal analysis of this cohort, clinical parameters of periodontal 
inflammation at baseline increased the risk if incident diabetes over a 13.84 year 
follow-up. As observed in the cross-sectional design (Chapter 2), serum markers 
for inflammation were not associated strongly with incident diabetes. No 
association with incident diabetes was seen with high baseline levels of IgG 
antibody levels to Porphyromonas gingivalis, and Actinobacillus 
actinmycetemcommitans, and this lack of association remained consistent when 
analyzing gingival crevicular fluid IL- and PG-E2 levels.  
 
  Another study found no association of clinical periodontal disease with 
incident diabetes in Japan. This study used fasting glucose levels similar to our 
study with a similar sample size (n=5,848), but the study duration was only 7 
years, which may not be sufficiently long enough to observe incident cases.57 
 
  Only one other study has found a positive association of baseline clinical 
periodontal disease and risk of subsequent diabtetes.56 In the National Health 
and Nutrition Examination Survey (NHANES) including 7,168 eligible 
participants, after 17 years of follow-up, the odds ratios for incident diabetes 
ranged from 1.5 (95% CI; 0.99-2.27) in advanced periodontal disease to 2.26 
(95%CI: 1.56-3.27) in moderate periodontitis. That study used the periodontal 
index to classify severity of periodontal inflammation, which looked at the visual 
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extent of gingival inflammation, presence or absence of pockets and tooth 
mobility to assign an averaged score. Our study used a comprehensive 
examination of probing measurements and bleeding upon probing, which are 
both the standard of care in clinical practice for diagnosing periodontal disease. 
The NHANES study also used death certificates, self-reports of diabetes 
requirement of pharmacologic treatment, and a health care facility stay with a 
discharge code of diabetes, which may have overestimated the number of new 
cases. Those participants were followed up at least one time. Our study was 
strengthened by yearly follow-up telephone calls, which was more likely to 
identify true incident diabetes as they occurred. 
 
Our results did not support the findings found in CVD outcome studies 
where systemic markers for periodontal inflammation were associated with an 
increased risk of cardiovascular disease. Both high antibody levels, 
Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans, have 
been found to increase the risk of CVD by an overall odds ratio of 1.75 (95%CI: 
1.32 to 2.34)54 No studies have assessed local inflammatory markers such as 
gingival crevicular fluid IL- and PG-E2 with cardiovascular or diabetes risks.  
Periodontal treatment for advanced peridontitis has not been shown to reduce 




 Our study had several strengths. First, ARIC is a large, community-based, 
biracial population in which there was standardized ascertainment of follow-up for 
approximately 14 years. Second, there were standardized measures of 
exposures, outcomes, and confounding variables in a rigorously monitored 
observational study, allowing us to explore the associated risk of incident 
diabetes with prior periodontal disease exposures.  This study is novel by 
combining both clinical and systemic measures specific to periodontal 
inflammation to assess diabetes as an outcome. This approach has been used to 
assess cardiovascular disease as an outcome, but unlike these other 
cardiovascular studies, an association of systemic inflammatory mediators with 
increased risk of diabetes was not shown.50, 51 Our study suggests that the 
association of periodontal inflammation with risk of diabetes is not the same as 
the association with the risk of cardiovascular disease.  In the cardiovascular 
disease infection hypothesis, several studies have validated the use of serum 
antibody level to the periodontal pathogens Porphyromonas gingivalis and 
Actinobacillus actinmycetemcommitans as a surrogate of periodontal clinic exam 
when assessing CVD risk. 51, 54 While these serum antibody levels do not indicate 
active or current periodontal disease, they have been used to study the level of 
prior exposure to periodontal inflammation and CVD risk.  
 
Nonetheless, the limitations should be kept in mind when interpreting our 
data. Firstly, this study also lacked longitudinal dental and medical exams. Teeth 
and their surrounding tissues provide the niche for periodontal pathogens and 
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gingival crevicular fluid. One study found that the elevated serologies no longer 
conferred increased cardiovascular risk in edentulous subjects. 51 Tooth loss data 
was not available after the baseline visit and dietary data was scant in this 
dataset.  Tooth loss may also influence dietary choices, caloric intake, 
cholesterol levels, body mass index and diabetes. While these were included in 
the model as confounders, tooth loss and diet may be a distinct separate 
pathway in the direction from periodontal disease to diabetes.  The longitudinal 
NHANES study found that participants with no teeth, had an odds ratio for 
incident diabetes of 1.3 (95%CI: 1.0-1.7), and those with advanced tooth loss (1-
7 teeth remaining) had an odds ratio of 1.7 (P<0.05). 56 Blood glucose 
assessment was also not available at follow-up to confirm incident diabetes in 
our study to confirm the telephone questionnaire responses. 
 
  A subsidiary analysis of baseline characteristics of 4, 864 individuals 
available at visit 4, but excluded from the periodontal examination, was 
performed (results not shown). The individuals excluded from our primary 
analysis had a higher proportion of African-Americans (39% vs. 24%), smokers 
(19% vs. 13%), increased caloric intake (1773 kcal/day vs. 1587kcal/day) and 
higher body mass-indices (31kg/m2 vs. 28.9kg/m2 ).  These aforementioned 
characteristics are known risk factors for diabetes. It is possible that exclusion of 
these individuals from the analysis may have resulted in an underestimated risk 
of diabetes. Additionally, 15 % (n=1,478) of the visit 4 participants were 
edentulous. If we assume that tooth loss is a surrogate for severe periodontal 
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disease status, then it is possible a large proportion of individuals with prior 
exposure to severe periodontal inflammation were not available for analysis, also 
resulting in an underestimated risk of diabetes.  
 
 
 We used the serum levels for inflammatory mediators’ highest quartile as 
the cut-point for high vs. low levels. Other studies used the highest tertile or 
quartile for the high level category for studying the association of periodontal 
disease with cardiovascular disease risk. 51 It is possible that the highest tertile or 
quartile may represent a unique population with the possibility for residual 
confounding.  
 
Performing multiple regressions for the five clinical and four systemic 
markers of inflammation increased the possibility of Type I error. The possibility 
of a false positive merely due to chance may also be due to the large number of 




The Atherosclerosis Risk in Communities (ARIC) Study is a community-
based prospective cohort providing a rich database with which to assess the 
effect of periodontal disease exposure on incident diabetes. This study helps 
answer the recent call by the Joint EFP/AAP consensus report for studies with 
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comprehensive clinical data, extent and severity of periodontal disease, level of 
glycemic control, and consideration of local and systemic pathways affected both 
periodontal disease and diabetes.53 This study served to contribute to the body of 
evidence that is largely lacking in the directionality of periodontal disease and 
subsequent incident diabetes.  
 
This study supports the hypothesis that clinical periodontal inflammation 
increases the risk of incident diabetes several years later.  An increase in 
bleeding upon probing appears to be both cross-sectionally associated with 
impaired glucose tolerance and longitudinally associated with the onset of 
incident diabetes. Since even minimal bleeding upon probing in this study was 
associated with prevalent pre-diabetes and future incident diabetes, a strong 
case is made to support patient education for prevention of periodontal disease 
to and study the effect of prevention of even mild periodontal inflammation on 
impaired glucose tolerance and diabetes. 
 
The serum markers specific to periodontal disease used in cardiovascular 
disease models do not appear to be helpful in assessing risk of incident diabetes. 
Though the American Heart Association’s Scientific Statement on Diabetes 
stated that “diabetes is a cardiovascular disease”, the mechanism of action may 
be very different.58 It may not be enough to study just a few systemic and local 
markers for periodontal disease to understand the mechanistic pathway of 






Periodontists’ attitudes, beliefs and standard of 
care in treating dental patients at risk for diabetes: 




The two-way relationship of periodontal disease and diabetes has been 
discussed in the literature for almost two decades, while the evidence to support 
the risk of diabetes associated with periodontal disease exposure is sparse.  The 
association of periodontitis with type 2 diabetes is recognized by local 
Periodontists (using a convenience sample survey of Washington DC area 
Periodontists), and the attitudes and beliefs of these specialists influence the 
standard of care in treating dental patients. When asked if it was appropriate to 
probe further about of diabetes risk factors in patients with periodontal disease 
and no diabetes diagnosis, most respondents (92.9%) agreed (agreed/ strongly 
agreed, n=39).  This survey suggests that practicing periodontists are aware that 
an association between periodontal disease and onset of type 2 diabetes, and 
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they appear aware of the importance of HbA1c testing in assessing glycemic 
control, whether this test is performed in the dental office or medical setting. This 
appears to parallel the consensus report of the Joint European Federation/ 
American Academy Workshop (EFP/AAP) guidelines to dentists for patients 




Periodontal disease is the most common inflammatory condition 
worldwide and diabetes is quickly becoming a global epidemic. The bidirectional 
pathway of periodontal disease and diabetes is not fully understood. While 
consistent evidence has shown that diabetes is related to periodontitis, emerging 
evidence suggests that periodontal disease may increase the risk of diabetes 
onset.  
 
Risk factors for type 2 diabetes include older age, obesity, and family 
history of diabetes, hypertension, high cholesterol levels and history of vascular 
disease.5 Modifiable lifestyle risk factors include smoking, physical activity level, 
weight loss, and healthy diet.5   While periodontal disease as a risk factor for 
incident diabetes has been proposed, sufficient evidence to quantify this 
association is lacking.59 
 
 The consensus report of the Joint European Federation/ American 
Academy Workshop (EFP/AAP) on periodontitis and systemic disease recently 
reviewed the role of periodontitis and the associated the risk of type 2 diabetes.  
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Their guidelines to dentists for patients without a diabetes diagnosis, but obvious 
risk factors for type 2 diabetes, include that the patients: 
“should be informed of their risk for having diabetes, assessed using a 
chair-side HbA1C test, and/or referred to a physician for appropriate 
testing and diagnostic care.” 53 
 
 This joint EFO/AAP suggests that evidence is emerging about the role of 
periodontal inflammation and the risk of incident diabetes, but concluded, “there 
is lack of clarity in the literature regarding the strength of this latter association”. 53 
This joint consensus report concluded that because of the “relative immaturity of 
the body of evidence for this purported relationship, the field is wide open and the 
gaps in knowledge are large”.53 Therefore, we conducted this survey to better 
understand the beliefs, perceptions, and current practices among local 




The association of periodontitis with diabetes with type 2 diabetes is 
recognized by Peridontists , and the attitudes and beliefs of these specialists 






Methods   
 
Identification of Potential Study Population 
 
We identified potential participants by examining the Periodontist listed by 
the American Academy Periodontology (AAP) as active members of the AAP.  
Additionally, only those listed within a 50-mile radius of Howard University were 
contacted. These periodontists self-selected for inclusion by choosing to 
participate in the survey. The institutional review board of Howard University 




The survey consisted of 6 questions. Three questions were rated on a 
four-point Likert-type scale and asked Periodontists about their practices in 
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treating patients who have not yet been diagnosed with type 2 diabetes. Two 
more survey items were unique questions that were asked based on 
respondent’s previous answers (using skip logic functions), and assessed the 
beliefs of the providers for practice decisions (ranking answers, and multiple 
answers). The final question was open-ended, which asked information about the 






 A confidential, self-administered survey instrument was developed with 
consultation with experts in survey design and methodology. Specialists in the 
field of dentistry assisted with the content and pre-tested the survey tool. The 
survey was modified to reflect changes suggested from these reviewers, and 
then it was transferred to an electronic format using a web-based survey service 
(www.surveymonkey.com). The electronic and written versions of the survey 
were then pilot tested by having reviewers complete the survey. Based on our 
pilot testing, the survey took between 3-5 minutes to complete, regardless 
whether the survey was done on paper or via the web-based format.  
 
 An e-mail invitation with an imbedded html link to the web-survey was sent 
to all 100 participants who agreed to take the survey, with two subsequent 
reminder e-mails sent at five days and ten days to non-responders, and a second 
telephone call at 7 days to this group. The invitation included an endorsement 
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from the Dean of Howard University College of Dentistry, who was also the 
interim Deputy Provost of Health Sciences at Howard University.  The invitation 
to participate in the survey was initiated in the middle of February 2014, and all 
responses to the middle of March 2014 were included for analysis. (See 
Appendix -Survey Questions from Chapter 4, p.120-120) 
 
 
Measurement and Data Analysis 
 
 All survey data were downloaded from the web-based application. Data 
management and analysis were completed using STATA 9.1 (Stata, College 
Station, TX).  Descriptive statistics for all data was reported, using means and 
percents. Questions about the likelihood of discussing risk factors and comfort 
level of discussing these risk factors were dichotomized (very unlikely/unlikely 
and very likely/likely), as were questions about appropriateness of discussing risk 
factors (strongly disagree/disagree and strongly agree/agree) and level of 
comfort in screening for diabetes (very comfortable/comfortable and very 
uncomfortable /uncomfortable), Questions requiring ranking of answers (most 
important=1, least important=5, or N/A) were given an average rating of 









 Of 146 members Periodontists listed by the American Academy of 
Periodontology within a 50-mile radius of Howard University, 12 were not 
practicing in the area (retired, moved, or on medical leave), and 28 were 
duplicate listings (same provider at multiple office addresses). This left 106 
periodontists eligible to participate in the survey, of which 6 declined during the 
first telephone call. The remaining 100 Periodontists agreed to participate and 
were sent web-based surveys. All 100 recipients chose the web-based format 
over telephone or paper responses. Of the 100 survey recipients, 42 initiated the 
survey and 39 completed the entire survey. The number of years in specialty 
practice ranged from 2 to 50 years (mean of 23.0 yrs, standard deviation 
SD=12.2 yrs).  
 
Risk Factors for Diabetes 
 
Periodontists were asked how likely they were to discuss risk factors for 
diabetes such as family history of diabetes, smoking, diet, exercise, and 
cardiovascular disease, in their periodontal patients who have not been 
diagnosed with diabetes. When asking about likelihood of discussing these risk 
factors 31.7% (n=13) were unlikely (very unlikely/ somewhat unlikely) and 68.3 
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(n=28) were likely (somewhat likely/ very likely) to discuss these risk factors.  
(Figure 9 and Table 19) When asked if it was appropriate to probe further about 
these risk factors in these same patients (periodontal disease and no diabetes 
diagnosis), 7.1% disagreed (strongly disagrees/ disagreed, n=3), and 92.9% 
agreed (agreed/ strongly agreed, n=39). (Figure 11, Table 20) 
 
Those who disagreed (n=2) in the second question provided reasons for 
not probing further about risk factors for diabetes in their patients. Neither 
responder cited inadequate time during the dental visit as an important reason for 
not discussing risk factors for diabetes, but did feel, in the order of most 
important to least important: this is a discussion best addressed by the primary 
care physician (average rating= 2.5/5), the patient would not expect the 
Periodontist to do this (average rating= 3/5), there is not enough evidence about 
the risk factors for diabetes (average rating= 4/5), there is not enough evidence 
to suggest that periodontal disease increases the risk of diabetes(average 
rating= 5/5) , and they were not comfortable discussing these risk factors 
(average rating= 5/5).  
 
Those who agreed in the second question (n=37), skipped to a question 
regarding the reasons for probing further about risk factors for diabetes in their 
patients. (Figure 12) In this discussion of risk factors of diabetes with patients, 
most felt; 1) This is an important teaching moment for the patient (89%, N=3), 2) 
There is sufficient evidence to suggest that periodontal disease increases the risk 
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of diabetes (81%, N=30), 3) This is a discussion best addressed by both the 
periodontist and the primary care physician (81%, N=30), 4) There is sufficient 
evidence about the risk factors for diabetes (76%, N=28), 5) There is adequate 
time during the appointment to have this discussion (70%, N=26), and 6) Feel 
comfortable discussing these risk factors (65%, N=24). They felt, in order of most 
important to least important: There is sufficient evidence about the risk factors for 
diabetes (average rating 2.5/5), there is sufficient evidence to suggest the 
periodontal disease increases the risk of diabetes (average rating= 2.75/5), they 
were comfortable discussing these risk factors (average rating= 3/5), this is an 
important teaching moment for the patient that should not be bypassed (average 
rating=3.3/5), this is a discussion best addressed by both the periodontist and the 
primary care physician (average rating=3.8/5), and there is adequate time during 
the appointment to have this discussion (average rating= 4.7/5). (Table 21) 
 
Screening for Type 2 Diabetes in the Dental Setting 
 
All survey respondents (n=39) were asked if they were comfortable 
performing a chair-side HbA1c test for assessing glycemic control, and 54.95% 
(n=20) felt uncomfortable, while 48. 7% (n= 19) were comfortable performing an 
HbA1c test. (Figure 13). Those uncomfortable in performing an in-office HbA1c 
test were asked the reasons for their discomfort, and 80% (n=16) felt that the 
physicians office was better equipped to perform such a test, 30% (n-6) did not 
feel comfortable performing this test in their office, 20% (n=4) did not feel they 
could be adequately reimbursed, 20% (n=4) said it was not a current standard of 
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care in dentistry, and 5% (n=1) reported that the effect of periodontal disease 
influencing HbA1c levels is not fully understood. (Figure 14)  
 
Those comfortable in performing an in-office HbA1c test were asked the 
reasons for their comfort level and 76.5% (n=13) reported that they felt 
comfortable performing the test in the periodontal practice, 53% (n=9) reported 
that the effect of periodontal disease influencing HbA1c levels is well understood, 
29.4% (n=5) felt the periodontal office is equipped to perform such a test, and 
5.9% (n=1) said that it is a current recommended standard of care in dentistry. 
This group did not report a concern for being reimbursed for this procedure (0%, 
n=0). (Figure 15) 
 
Of those uncomfortable in performing the HbA1c test in the dental office, 
80% (N=16) felt that the physician’s office is better equipped to perform such as 
test. (Figure 14) Over 50% of those comfortable in performing this test for 
glycemic control in the dental office felt that the effect of periodontitis on HbA1c is 





























Table 19:Survey Response to Likelihood of Discussing Risk Factors for 
Diabetes. 
Answer Choices N (%) 
Very Unlikely 6(14.63) 
Some Unlikely 7(17.07) 
Somewhat Likely 12(29.27) 
Very Likely 16(39.02) 













Figure 11-Survey Response to Appropriateness of Discussing Risk Factors 








Table 20-Survey Response to Appropriateness of Discussing Risk Factors 
of Diabetes 
Answer Choices N (%) 
Strongly Disagree 1 (2.38) 
Disagree 2 (4.76) 
Agree 30 (71.43) 
Strongly Agree 9 (21.43) 












Figure 12-Survey Response to Reasons for Discussion Risk Factors for 
Diabetes 
 




















Table 21-Survey Response Rankings of Reasons for Discussion Risk 
Factors for Diabetes  





















































































































































































Table 22 -Survey Response for Comfort Level of Screening for Diabetes 
Answer Choices N (%) 
Very Uncomfortable 6 (15.38) 
Uncomfortable 14 (35.9) 
Comfortable 10 (25.64) 
Very Comfortable 9 (23.08) 

































The position papers from the AAP have been discussing the two-way 
relationship for almost two decades. While evidence of the effect periodontal 
disease on glycemic control in type 2 diabetes populations has been well 
documented, the Joint EFP/AAP consensus report concluded that evidence is 
just emerging.53 This EFP/AAP group also gave recommendations for future 
research that will strengthen what is known about this association. Approximately 
76% of respondents to our survey felt that there is sufficient evidence to support 
periodontal disease increase the risk of type 2 diabetes, though a recent review 
concluded such studies are “sparse”.59 
 
Over 50% of those comfortable in performing the test for glycemic control 
in the dental office felt that the effect of periodontitis on HbA1c is well 
understood. A review of literature identified a study (n=961) in Japan reporting 
over ten years, each millimeter increase in periodontal probing depth 
corresponded to an HbA1c of 0.13% (p=0.007).23 In contrast, a meta-analysis of 
10 interventional studies of periodontal treatment found that successful 
periodontal therapy did not result in statistically significant changes in glycemic 
control in diabetic subjects, with 0.57% reduction in A1c measures (p=0.82).24 
Only 456 subjects were included in all ten studies and larger studies with 
randomized clinical trials are needed to determine the benefit of periodontal 
therapy on glycemic control in patients with diabetes.  
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 Respondents to this survey were all Members of the American Academy 
of Periodontology (AAP) and displayed, on average over two decades of 
experience in private practice. Members of this Academy have a subscription to 
the Journal of Periodontology and are sent position papers, consensus reports, 
and reviews from the AAP about topics in Periodontology. This is a professional 
population who we expect to be up to date in periodontal literature. Most 
responders were likely to discuss risk factors for diabetes (68%, n=28), and 
probe further about these risk factors at initial appointments for patients with a 
history of periodontitis. This would be expected since, medical history 
questionnaires, and review of the medical history by the provider, are standards 
of care for initial consultations. In these medical history forms, smoking, diet, and 
cardiovascular disease are common items that are included. (See Appendix- 
Figure 18- Sample checklist for dentists provided by the AAP) While these 
are risk factors for type-2 diabetes, patients positive for these risk factors may 
also warrant frequent oral cancer screenings, be on prescription medication, or 
be contra-indicated for some procedures. Thus, the 93% (n=39) responders that 
would probe further in patients with risk factors for diabetes is not surprising.  
 
This study had several limitations. This study was a convenience sample 
of the Washington, D.C. metropolitan area. It gives an initial look at what the 
beliefs of local Peridontists have about the standard of care in the profession. 
The web-based survey made it easy to send, receive and complete the questions 
and no recipients requested a paper format of the survey, thus shortening the 
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time to receive completed surveys for analysis. Response rate may not have 
been increased if paper surveys were mailed.  Our response rate (39%) is in the 
typical range from 20-47% for electronic surveys.60  
 
The sampling the AAP members may not be representative of other 
practicing periodontists, who do not have easy access to the Journal of 
Periodontology, position papers, consensus reports, and reviews from the AAP 
about topics in Periodontology. This group would be expected to be the most 
informed group, with an information bias due to the availability of AAP 
publications, as their knowledge may be better than other specialists in the 
community. Additionally, general dentists often treat mild, to moderate forms of 
periodontal disease, so limiting the survey to periodontists may miss the beliefs    
of the standard of care in treating the many patients with early periodontal 
disease in this geographic area. Our findings may not be generalizable to all 
Periodontists and cannot be applied to all providers (general dentists) treating 
patients with periodontal disease. 
 
Respondents who answer web-based e-mails may be a biased towards 
providers who are inter-net savvy. These individuals can access the most current 
literature on the web and may possess an informational bias. Additionally, a local 
Periodontist, with whom some of the survey recipients were acquainted, made 
the initial telephone calls. Thus responders may also have responded with an 
appeasement bias to please a fellow colleague. 
 102 
 
Questions in the survey had closed-ended answers to which respondents 
were asked to choose answers. These answers were presumed to be the most 
likely answers based by experts in both dentistry and survey design. While such 
a survey is places less burden of time on respondents and is simple to analyze, it 
is possible however, that if the questions were open-ended, local Periodontists 




The association of periodontitis with diabetes with type 2 diabetes is 
accepted by local Peridontists (using a convenience sample survey of 
Washington DC area Periodontists), and the attitudes and beliefs of these 
specialists influence the standard of care in treating dental patients. When asked 
if it was appropriate to probe further about of diabetes risk factors in patients with 
periodontal disease and no diabetes diagnosis, most respondents (92.9%) 
agreed (agreed/ strongly agreed, n=39).  
 
The local Periodontists surveyed felt, in order of most important to least 
important: there is sufficient evidence about the risk factors for diabetes, there is 
sufficient evidence to suggest that periodontal disease increases the risk of 
diabetes, they were comfortable discussing these risk factors, this is an important 
teaching moment for the patient that should not be bypassed, this is a discussion 
best addressed by both the periodontist and the primary care physician, and 
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there is adequate time during the appointment to have this discussion. This 
survey suggests that practicing periodontists are aware that there is an 
association between periodontal disease and the onset of type 2 diabetes.  
 
Those surveyed also appear aware of the importance of HbA1c testing in 
assessing glycemic control, whether this test is performed in the dental office or 
medical setting. This appears to parallel the consensus report of the Joint 
European Federation/ American Academy Workshop (EFP/AAP) guidelines to 
dentists for patients without a diabetes diagnosis, but obvious risk factors for type 
2 diabetes, where patients: 
 
“ should be informed of their risk for having diabetes, assessed using a 
chair-side HbA1C test, and/or referred to a physician for appropriate 
testing and diagnostic care.” 53 
 
Overall, the local Periodontists responding to the survey appear to be 













Periodontal disease has been proposed as one source of inflammation 
that might predispose adults to developing diabetes. Though the hypothesis of a 
bidirectional pathway between periodontal disease and diabetes has been 
proposed, few studies have addressed periodontal disease before the 
occurrence of diabetes.19 Localized periodontal inflammation is now known to 
have systemic effects on general health. 40,41 Compromised oral health may 
increase the risk of a pre-diabetic status meditated through inflammation. Our 
study, which used both clinical exams and markers for inflammation, looked at 
the association of periodontal disease exposure and its’ association with pre-
diabetes and diabetes risks. 
In our cross- sectional analysis, we found clinical periodontal measures for 
inflammation were associated with the likelihood of impaired fasting glucose. This 
association seemed to hold true for individuals with only slight bleeding upon 
probing, with deeper probing measurements, or more severe gingival bleeding 
upon probing. However, a dose response relationship was not observed with 
increasing severity of periodontal inflammation. Compared with individuals with 
normo-glycemic levels, adults with pre-diabetes using fasting glucose levels, had 
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an increased odds of periodontal clinical inflammation that remained even after 
adjustment for lifestyle and co-morbidity covariates.  Participants with more 
severe periodontal clinical inflammation had an increased odds of impaired 
fasting glucose. Compared to individuals in Category I, the odds ratio for 
impaired fasting glucose in Category V was 2.1 (95% CI: 1.6-2.8) in an 
unadjusted model. This relationship remained in the fully adjusted model with an 
odds ratio of 1.5 (1.1--2.1) in this highest category (one or more sites with a 
probing depth >4 mm and bleeding upon probing 50%).  
 
To further explore the relationship, between prediabetes and periodontal 
inflammation, we performed four additional analyses using markers of systemic 
inflammation  (serum antibody levels to the periodontal pathogens 
Porphyromonas gingivalis and Actinobacillus actinmycetemcommitans), and 
markers of localized inflammation (gingival crevicular fluid levels of IL-1 (GCF- 
IL-1) and gingival crevicular fluid levels of prostaglandin (PG-E2) However, no 
significant association was observed between pre-diabetes or undiagnosed 
diabetes and any of those inflammation markers.  
 
In a longitudinal design, adults with clinical periodontal measures for 
inflammation were associated with incident diabetes. During 13.84 years of follow 
up 1,967 individuals developed Type 2 diabetes of the total (n= 5,819) 
participants initial visit 4.  Compared with individuals with minimal bleeding and 
probing measures, the hazard of incident diabetes appears to be 1.2 times higher 
in adults with moderate to severe clinical periodontal inflammation (Category IV 
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and Category V both having 95%CI: 1.0-1.6, P<0.001). However Category III did 
not display this increasing significant trend with a hazard ratio of 1.0 (95% CI:0. 
8-1.20).  Our results did not support the findings of CVD outcomes where 
systemic markers for periodontal inflammation were associated with an increased 
risk of cardiovascular disease. The hazard of incident diabetes appeared to be 
the same in adults with high levels vs. low levels of antibodies to Porphyromonas 
gingivalis and Actinobacillus actinmycetemcommitans. Similarly, no increase in 
incident diabetes could be seen in high vs. low levels of gingival crevicular fluid 
levels of IL-1 and PG-E2. 
    
Using a convenience sample survey of Washington DC area 
Periodontists, and the attitudes, beliefs, and the standard of care in treating 
dental patients at risk for type 2 diabetes were assessed. Respondents to this 
survey were all Members of the American Academy of Periodontology (AAP) and 
displayed, on average over two decades of experience in private practice.  
Approximately 76% of respondents to our survey felt that there is sufficient 
evidence to suggest that periodontal disease increases the risk of type 2 
diabetes, though a recent review concluded such studies are “sparse”.59   Almost 
50% of those surveyed were comfortable in performing the HbA1c test for 
glycemic control in the dental office and of those comfortable, 53% felt that the 






Our studies supports that hypothesis that clinical periodontal inflammation 
is associated with impaired glucose tolerance and this exposure may increase 
the risk of incident diabetes several years later.  An increase in bleeding upon 
probing appears to be both cross-sectionally associated with impaired fasting 
glucose and longitudinally associated with the onset of incident diabetes. A dose- 
response relationship was not observed with increasing severity of periodontal 
inflammation. These results are to be expected since probing depths give a 
measure of prior periodontal attachment loss, while bleeding upon probing 
assesses current inflammation. A periodontal exam that combines probing depth 
and bleeding scores gives an accurate assessment of prior and current 
periodontal status, and both are used together in the examination and diagnosis 
of dental patients in the clinical setting.  
 
An assessment of risk of impaired fasting glucose may be performed 
easily in the dental office. This requires a dental exam commonly and currently 
performed by dental providers. The use of immunoassays, which are costly, and 
technically demanding, may not be necessary to define the relationship of 
periodontal disease with pre-diabetes.   
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Presumably, the prevention of gingival inflammation may reduce the risk 
of diabetes onset. The reduction of periodontal disease, and then diabetes, has 
potential to slow the growing epidemic proportions of both diseases. Our studies 
contribute to the sparse evidence for the association of periodontal association 
with pre-diabetes and future incident diabetes. Additionally, we have provided 
preliminary evidence to support the hypothesis that exposure to even mild 
gingival inflammation may have systemic effects on glycemic control. This finding 
is novel, since other studies found a dose-response relationship, with more 
severe inflammation having more effect on glycemic control and type 2 
diabetes.22, 23 
 
The Atherosclerosis Risk in Communities (ARIC) Study, a community-
based prospective cohort provided a rich database with which to assess the 
effect of periodontal disease exposure on incident diabetes. This study helps 
answer the recent call by the Joint EFP/AAP consensus report for studies with 
comprehensive clinical data, extent and severity of periodontal disease, level of 
glycemic control, and consideration of local and systemic pathways affected by 
both periodontal disease and diabetes.53 Our studies served to contribute to the 
body of evidence that is largely lacking in the directionality of periodontal disease 






 The strength of this overall dissertation is that it serves to contribute to the 
lack of evidence to support the directionality of periodontal disease exposure and 
the associated risk of pre-diabetes and diabetes. The recent recommendation for 
future research in this area by the for more evidence in consensus report of the 
Joint European Federation/ American Academy Workshop (EFP/AAP) includes a 
“comprehensive assessment of clinical measures of periodontal inflammation 
and biochemical markers of inflammation in blood and saliva”.53  Our studies 
used a database with complete periodontal assessments, serum antibody levels 
to periodontal pathogens, and gingival crevicular fluid levels of inflammatory 
markers to asses periodontal disease exposure.  
 
  The use serum antibody levels to periodontal pathogens as a surrogate for 
disease exposure is controversial.  While validated in other studies51,54 , use of 
antibody levels to Porphyromonas gingivalis and Actinobacillus 
actinmycetemcommitans as measure of past severity of periodontal inflammation 
is not accepted as a standard measurement of periodontal disease by the 
Academy of Periodontology and not a current recommendation for assessment of 
type 2 diabetes risk. However, these markers have been used in mechanistic 
studies of cardiovascular disease risk, and helped suggest in our study that a 
different biologic pathway may be involved when assessing type 2 diabetes risk. 
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This data will help define the biologic mechanisms and provide direction for 
future interventions.  
 
 As the prevalence of diabetes and periodontitis increases, dentists will 
likely see an increasing number of patients with diagnosed and undiagnosed 
diabetes. The American Dental Association now recommends that dental offices 
be equipped with glucometers. Patient education about the importance of 
prevention and treatment of periodontal disease and diabetes is the role of both 
physicians and dentists.61 
 
 Insurance coverage for dental care should be mandated for people with 
diabetes. The health of the public will be served by public policies which focus on 
the prevention and control of periodontitis and diabetes.62 Since the prognosis of 
periodontal disease is best treated at its earliest stages, programs aimed at 
patient education and health promotion may limit the burden of sequelae 




Since even minimal bleeding upon probing in this study was associated 
with prevalent pre-diabetes and future incident diabetes, a strong case is made 
to support patient education for prevention of periodontal disease to and study 
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the effect of prevention of even mild periodontal inflammation on impaired 
glucose tolerance and diabetes. 
 
  Assessment younger populations with mild gingival inflammation, 
followed longitudinally, may provide evidence of the earliest effects of periodontal 
inflammation on the risk of impaired glucose levels and incident diabetes. 
Studying gingivitis, the earliest form of periodontal inflammation, may yield the 
most sensitive ascertainment of the effect of subtle changes of oral health on 
diabetes. 
 
 The cost-effectiveness and outcomes of screening programs in the pre-
diabetic state should be reliably assessed in relation to oral health. This can 
performed if medical providers routinely refer “at risk” individuals to dental 
professionals.  
 
Finally, the relationship between periodontal disease and diabetes is 
complex and not likely to be understood by a single study regardless of its 
design. Synthesis of existing and future studies will be helpful in elucidating these 
relationships and provide the direction for public health policies aimed at 











































Figure 16: Clinical Appearance of Stages of Periodontal Disease 
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Preamble to Telephone and Internet Survey from Chapter 4 
 
 





Periodontal disease is the most common inflammatory condition worldwide and 
diabetes is quickly becoming a global epidemic. The bidirectional pathway of 
periodontal disease and diabetes is not fully understood. While consistent 
evidence has shown that diabetes is related to periodontitis, emerging evidence 
suggests that periodontal disease may increase the risk of diabetes onset.  
 
Your participation in the survey will help answer important questions regarding 
the direction of future research and patient education in this important area of 
oral health. In addition we will better understand what is the attitude of current 
best practices in managing periodontal patients at risk for diabetes. 
 
I hope that you will take the time to complete these six questions. We expect that 
this survey will take 3-5 minutes to complete. Your consent to participate is 
assumed by your completing the survey. All data will remain confidential and will 
only be published in aggregated form. Individual respondents will not be 
identified in publications. 
  





Leo (Signed by Dean Leo Rouse) [Reviewed by Dean Rouse on 11/14/13, 
electronic signature was added to web-based survey] 
 
 
Leo E. Rouse DDS, FACD 
Past President of American Dental Education Association 
Interim Deputy Provost for Health Sciences 






Survey Questions from Chapter 4: 
 
1) If your patient has a history of periodontal disease, but no reported medical 
history of diabetes, how likely are you to discuss the risk factors of diabetes 
(such family history of diabetes, smoking, diet, exercise, cardiovascular disease) 
during the initial consultation appointment: 
 
Very Unlikely  Somewhat Unlikely Somewhat likely  Very Likely   
 
2) Do you think it is appropriate to probe further about risk factors of diabetes 
(such family history of diabetes, smoking, diet, exercise, cardiovascular disease) 
in your patients without a current medical history of diabetes? 
 
 Strongly Disagree Disagree Agree  Strongly Agree 
 
3a) You answered that you do not agree/strongly disagree that asking about risk 
factors of diabetes is appropriate in your non-diabetic patients. Is this because: 
(Number all that apply, if any, in order of importance, i.e. #1-most important 
reason)  
i) There is not enough evidence to suggest periodontal disease 
increases the risk of diabetes. 
ii) There is not enough evidence about the risk factors for diabetes. 
iii) I don’t feel comfortable discussing these risk factors. 
iv) There is insufficient time during the appointment to have this 
discussion. 
v) This is a discussion best addressed by the patient’s primary care 
physician. 




3b) You answered that you agree/strongly agree that asking about risk factors of 
diabetes is appropriate in your non-diabetic patients. Is this because: (Number all 
that apply, if any, in order of importance, i.e. #1-most important reason)  
i) There is sufficient evidence to suggest periodontal disease 
increases the risk of diabetes. 
ii) There is sufficient evidence about the risk factors for diabetes. 
iii) I feel comfortable discussing these risk factors. 
iv) There is adequate time during the appointment to have this 
discussion. 
v) This is a discussion best addressed by both the periodontist and 
the primary care physician. 
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vi) This is an important teaching moment for the patient that should not 
be bypassed. 
 
4) In patients that do not have a diagnosis of diabetes, but have obvious risk 
factors for diabetes, how comfortable are you in assessing glycemic control using 
a chair-side HbA1C test? 
 Very Uncomfortable Uncomfortable  Comfortable Very Comfortable 
 
5a) You answered that you were not comfortable in performing a chair-side 
HbA1C test. Is this because (Check all that best apply): 
i) The effect of periodontal disease influencing HbA1C levels is not 
fully understood. 
ii) The primary care physician’s office is better equipped to perform 
such a test. 
iii) I do not feel comfortable performing such a test in the periodontal 
practice. 
iv) I cannot be adequately reimbursed by dental insurance companies 
for this procedure at this time. 
v) This test is not a current recommended standard of care in 
dentistry. 
 
5b) You answered that you were comfortable in performing a chair-side HbA1C 
test. Is this because (Check all that best apply): 
i) The effect of periodontal disease influencing HbA1C levels is well 
understood. 
ii) The periodontal office is equipped to perform such a test. 
iii) I feel comfortable performing such a test in the periodontal practice. 
iv) Patients for this procedure can adequately reimburse me at this 
time. 
v) This test is a current recommended standard of care in dentistry. 
 
The last question tells us something about you as a survey respondent: 
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